Treatment of diseases with biological materials or biological response modifiers, such as the use of GENES; CELLS; TISSUES; organs; SERUM; VACCINES; and humoral agents.
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.
Drugs that are used to treat RHEUMATOID ARTHRITIS.
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
Used in the manufacture of acetophenetidin.
Antibodies produced by a single clone of cells.
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
Drugs used to treat or prevent skin disorders or for the routine care of skin.
Inflammation of the joints of the SPINE, the intervertebral articulations.
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.
Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.
Antibodies obtained from a single clone of cells grown in mice or rats.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
The practice of prescribing or using a drug outside the scope of the drug's official approved label as designated by a regulatory agency concerning the treatment of a particular disease or condition.
A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
Substances that reduce or suppress INFLAMMATION.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
Arthritis of children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
A ligand that binds to but fails to activate the INTERLEUKIN 1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
The process that reverts CELL NUCLEI of fully differentiated somatic cells to a pluripotent or totipotent state. This process can be achieved to a certain extent by NUCLEAR TRANSFER TECHNIQUES, such as fusing somatic cell nuclei with enucleated pluripotent embryonic stem cells or enucleated totipotent oocytes. GENE EXPRESSION PROFILING of the fused hybrid cells is used to determine the degree of reprogramming. Dramatic results of nuclear reprogramming include the generation of cloned mammals, such as Dolly the sheep in 1997.
Tumors or cancer of the human BREAST.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
A voluntary organization concerned with the prevention and treatment of cancer through education and research.
A general term for various neoplastic diseases of the lymphoid tissue.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
The urea concentration of the blood stated in terms of nitrogen content. Serum (plasma) urea nitrogen is approximately 12% higher than blood urea nitrogen concentration because of the greater protein content of red blood cells. Increases in blood or serum urea nitrogen are referred to as azotemia and may have prerenal, renal, or postrenal causes. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
The number of PLATELETS per unit volume in a sample of venous BLOOD.
A specialty field of radiology concerned with diagnostic, therapeutic, and investigative use of radioactive compounds in a pharmaceutical form.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)

New treatment strategies for malignant gliomas. (1/231)

Although survival in patients with malignant gliomas remains limited, there is renewed optimism with the emergence of novel treatment strategies. Cytotoxic agents such as temozolomide and CPT-11 have shown promising clinical activity. Biological treatments for brain tumors, including antisense oligonucleotides, gene therapy, and angiogenesis inhibitors, are also being evaluated in clinical trials. Delivery strategies have been developed to overcome challenges presented by the blood-brain barrier. These noteworthy treatments, alone or in combination, may ultimately prolong survival and enhance quality of life in this group of patients.  (+info)

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. (2/231)

Genetically engineered, neuroattenuated herpes simplex viruses (HSVs) expressing various cytokines can improve survival when used in the treatment of experimental brain tumors. These attenuated viruses have both copies of gamma(1)34.5 deleted. Recently, we demonstrated increased survival of C57BL/6 mice bearing syngeneic GL-261 gliomas when treated with an engineered HSV expressing IL-4, as compared with treatment with the parent construct (gamma(1)34. 5(-)) alone or with a virus expressing IL-10. Herein, we report construction of a conditionally replication-competent mutant expressing both subunits of mIL-12 (M002) and its evaluation in a syngeneic neuroblastoma murine model. IL-12 induces a helper T cell subset type 1 response, which may induce more durable antitumor effects. In vitro studies showed that, when infected with M002, both Vero cells and murine Neuro-2a neuroblastoma cells produced physiologically relevant levels of IL-12 heterodimers, as determined by ELISA. M002 was cytotoxic for Neuro-2a cells and human glioma cell lines U251MG and D54MG. Neurotoxicity studies, as defined by plaque-forming units/LD(50), performed in HSV-1-sensitive A/J strain mice found that M002 was not toxic even at high doses. When evaluated in an intracranial syngeneic neuroblastoma murine model, median survival of M002-treated animals was significantly longer than the median survival of animals treated with R3659, the parent gamma(1)34.5(-) mutant lacking any cytokine gene insert. Immunohistochemical analysis of M002-treated tumors identified a pronounced influx of CD4(+) T cells and macrophages as well as CD8(+) cells when compared with an analysis of R3659-treated tumors. We conclude that M002 produced a survival benefit via oncolytic effects combined with immunologic effects meditated by helper T cells of subset type 1.  (+info)

Where is biological therapy going? (3/231)

The substantial progress in our understanding of molecular and cellular biology has allowed us to design biological therapeutics ('biologicals') with defined targets and effector functions. These biologicals have greatly contributed to our current knowledge of pathogenetic mechanisms in autoimmune diseases. However, although some of the biologicals have been extremely successful in treating the symptoms of chronic inflammation, biological therapy has not yet met the expectations of permanently silencing the chronic immune response. In this commentary we discuss current concepts and future directions of biological therapy, and the potential usefulness of biologicals as a treatment of human autoimmune diseases in appropriate critical applications with the use of suitably designed agents.  (+info)

Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. (4/231)

There is an increasing scientific and commercial interest in the use of beneficial microorganisms, or "probiotics," for the prevention and treatment of disease. The microorganisms most frequently used as probiotic agents are lactic-acid bacteria such as Lactobacillus rhamnosus GG (LGG), which has been extensively studied in recent literature. Multiple mechanisms of action have been postulated, including lactose digestion, production of antimicrobial agents, competition for space or nutrients, and immunomodulation. We have reviewed recent studies of probiotics for the treatment and control of infectious diseases. Studies of pediatric diarrhea show substantial evidence of clinical benefits from probiotic therapy in patients with viral gastroenteritis, and data on LGG treatment for Clostridium difficile diarrhea appear promising. However, data to support use of probiotics for prevention of traveler's diarrhea are more limited. New research suggests potential applications in vaccine development and prevention of sexually transmitted diseases. Further studies are needed to take full advantage of this traditional medical approach and to apply it to the infectious diseases of the new millennium.  (+info)

Update on the treatment of systemic lupus erythematosus: therapeutic highlights from the Sixth International Lupus Conference. (5/231)

The studies presented at the conference indicate that new therapeutic agents are effective for patients with SLE. Some of the agents (high dose cyclophosphamide) may be given to patients with refractory disease while others (low dose cyclophosphamide, and MMF) may be used as a first-line drug. The current data on biologic agents are still preliminary and their exact role in SLE needs to be determined.  (+info)

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. (6/231)

BACKGROUND: Gemcitabine and vinorelbine are two of the most active third-generation agents for the treatment of advanced nonsmall cell lung carcinoma (NSCLC). The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC. METHODS: A total of 78 patients were treated on the current Phase II trial of front-line or second/third-line therapy with gemcitabine and vinorelbine in NSCLC. Eligible patients manifested either untreated disease (n = 42) or had received at least one but not more than two prior chemotherapy regimens (n = 36). The median age was 57.5 years (range, 33-79) with 57 men (73%) and 21 women (27%). The median performance status was one (range, one to two). The initial eight patients (four untreated and four previously treated) were treated at a previously established maximum tolerated dose of vinorelbine (30 mg/m(2)) and gemcitabine (1000 mg/m(2)) on Days 1, 8, and 15, with significant myelosuppression seen in five out of eight patients requiring dose omission in the first cycle. The next 70 patients received a reduced dose of vinorelbine (25 mg/m(2)) followed by gemcitabine (900 mg/m(2)) on Days 1, 8, and 15. RESULTS: Seventy eight patients were treated. Fifteen (36%) of the 42 evaluable patients who received front-line therapy had objective responses and 14 (33%) had stable disease. In the patients with prior treatment, 6 (17%) of 36 patients had partial response and 18 patients (50%) had stable disease. Median survival time for the previously untreated patient group was 10.1 months, with a one year survival of 43% and a two year survival rate of 32%. For the previously treated patients, the median survival time was 8.5 months, with a one year survival rate of 30%. Toxic effects were notable for significant myelosuppression, with > or =Grade 3 granulocytopenia seen in 55% of the patients on the untreated arm and 67% of the patients on the previously treated arm. Additionally, 9.5% and 13.9% (untreated and previously treated), respectively, of these patients experienced Grades 3 and 4 thrombocytopenia at some point in their treatment. A full dose delivery analysis showed that this myelosuppression resulted in Course 1, Day 15 skipped doses (even at the reduced dose level) in 42% of previously untreated patients and 47% of pretreated patients. Other side effects seen at Grades 3 and 4 in previously untreated and treated patients included anemia (9.5% and 2.8%), asthenia (4.8% and 5.5%), infection (14.3% and 5.6%), pain (9.5% and 19.4%), and pulmonary complications (4.8% and 13.8%). CONCLUSIONS: Gemcitabine/vinorelbine is an active, well-tolerated combination in both front-line and second/third-line therapy for Stage IIIB/IV NSCLC. The response rate, median survival rate, and one year survival rate compare favorably with platinum-based regimens. The toxicity profile of the gemcitabine/vinorelbine combination was quite favorable, with minimal Grade 3 and 4 toxic effects aside from granulocytopenia, which resulted in numerous Day 15 skipped doses but no significant febrile neutropenia or infection. The combination of gemcitabine and vinorelbine could be a useful regimen in standard clinical practice and has the potential for efficient combination with biologic/targeted therapy. Multiple randomized trials of this combination versus platinum combinations are now ongoing [corrected].  (+info)

Yoghurt biotherapy: contraindicated in immunosuppressed patients? (7/231)

A fatal case of Lactobacillus rhamnosus septicaemia after prolonged oral vancomycin for recalcitrant Clostridium difficile infection is reported. The patient was immunosuppressed with cyclophosphamide and steroids for Sjogren's syndrome. The administration of Lactobacillus spp as "biotherapy" may be hazardous in such circumstances.  (+info)

Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. (8/231)

Live attenuated measles virus (MV-Edm) has potent oncolytic activity against myeloma xenografts in mice. Therapy of multiple myeloma, a disseminated plasma cell malignancy, would require systemic administration of the virus. Thus, the virus should ideally be targeted to infect only myeloma cells to minimize collateral damage to normal tissues: viral binding to its natural receptors must be ablated and a new specificity domain that targets entry into myeloma cells be added. This study covers 2 critical steps toward generating such a retargeted virus: (1) a new specificity domain against the plasma cell marker CD38 was constructed in the form of a single-chain antibody (scFv) and (2) display of that scFv on the measles viral envelope glycoprotein successfully redirected virus entry through CD38 expressed on target cells devoid of the natural MV receptors. The anti-CD38 scFv was tethered to the C-terminus of the hemagglutinin (H) glycoprotein of MV-Edm through a Factor Xa protease cleavable linker. Immunoblot analysis demonstrated that the scFv was efficiently incorporated into recombinant viral particles. Replication of MV-alpha CD38 was not hindered by the scFv, reaching titers comparable to MV-Edm. Chinese hamster ovary (CHO) cells were resistant to infection by MV-Edm and MV-alpha CD38. In contrast, CHO cells expressing CD38 became susceptible to infection by MV-alpha CD38 but not MV-Edm. Removal of the displayed scFv rendered MV-alpha CD38 noninfectious on CHO-CD38 cells. Tumorigenicity of CHO-CD38 cells in immunocompromised mice was significantly attenuated by MV-alpha CD38, resulting in enhanced survival of these mice compared with the control group.  (+info)

Mark Davis, ND. Fecal microbiota transplantation (FMT) is also known as human probiotic infusion, fecal transplant, fecal bacteriotherapy, fecal slurry, and gut flora rehabilitation and has been humorously referred to as transpoosion. The procedure consists of collecting stool from a healthy donor; suspending it in water, normal saline, or 4% milk; and administering it to the patient (most frequently via enema but also via colonoscope, nasogastric or nasoduodenal tube, rectal tube, or even [anecdotally] orally as a milkshake1). This massive infusion of healthy colonic bacteria has been used as far back as the 17th century in veterinary medicine to treat digestive disturbances2 and as early as 1958 in humans to treat pseudomembranous colitis.3. Fecal microbiota transplantation has a 90% success rate in curing Clostridium difficile-associated chronic diarrhea, colitis, and pseudomembranous colitis,4 which affect half a million and kill 15 000 to 20 000 Americans per year.5 Fecal microbiota ...
TY - JOUR. T1 - Fecal microbiota transplantation for recurrent Clostridium difficile infection. AU - Brandt, Lawrence J.. AU - Reddy, Sheela S.. PY - 2011/11. Y1 - 2011/11. N2 - With the increasing prevalence of recurrent/refractory Clostridium difficile infection (CDI), alternative treatments to the standard antibiotic therapies are being sought. One of the more controversial of such alternative treatments is fecal microbiota transplantation (FMT). Although the notion of FMT is foreign - even startling - and not esthetic to most people, the concept has been around for many decades. Its benefit and efficacy dates back ,50 years to its use for staphylococcal pseudomembranous colitis, and now FMT is showing a great promise as an inexpensive, safe, and highly efficient treatment for recurrent and refractory CDI. Moreover, with a better understanding of the intricacies of the colonic microbiome and its role in colonic pathophysiology, FMT has the potential to become the standard of care for CDI ...
The investigators propose to use autologous fecal microbiota transplantation (AFMT) to acute myeloid leukemia (AML) patients treated with intensive chemotherapy and antibiotics in order to restore the balance of their intestinal microbiome and thereby eradicate treatment-induced multidrug resistant bacteria (MDRB), infection-related complications, as well as sequelae to the gastrointestinal tract. Therefore, the investigators propose to perform a single-arm multicentre prospective fecal microbiota transplantation (FMT) trial in AML patients receiving intensive chemotherapy, and who are usually heavily treated with broad-spectrum antibiotics during aplasia that generate a profound status of dysbiosis. For this purpose, at the time of admission and AML diagnosis, patients will be requested to donate stools that will be comprehensively screened, and if deemed appropriate according to protocol criteria, conditioned and stored frozen until future processing and transplantation after aplasia completion ...
Post written by Jessica R. Allegretti, MD, MPH, from Brigham Womens Hospital, Boston, Massachusetts, USA. Clostridium difficile infection (CDI) is the most common healthcare-associated infection in the United States. Recently, fecal microbiota transplantation (FMT) has emerged as an effective and safe therapy for recurrent CDI; however, there is no standardized clinical approach. Given the rapid…
Dysbiosis plays a major role in the etiology of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) is a new promising option for IBD treatment. We aimed to assess the effectivene
Phys.org Science News Wire : Largest Planned Fecal Microbiota Transplantation (FMT) study enrolls first patient -- a press release is provided to you ìas isî with little or no review from Phys.org staff.
NIAID-supported researchers have shown that autologous fecal microbiota transplantation (auto-FMT) is a safe, effective way to replenish beneficial gut bacteria in cancer patients requiring intense antibiotics during allogenic hematopoietic stem cell transplantation. Auto-FMT resulted in the recovery of beneficial gut bacteria to near baseline levels within days, restoring digestive, immune and other functions. With standard care, beneficial bacteria typically take weeks to recover from antibiotic treatment, leaving patients at risk of other infectious diseases.
We established a standard bacteria isolation from donated fresh stool in lab.Then the bacteria is transplanted to mid-gut (at least below the second part of duodenum ) through regular gastroscope. Participants in this study will be randomly assigned to receive fecal microbiota transplantation only once or traditional therapy, and accept follow-up for at least one year. Blood tests,OGTT and magnetic resonance spectroscopy will be used to assess participants at study start and at study completion ...
Biological therapies in the systemic management of psoriasis; International Consensus Conference. Br J Dermatol, 151 (2004), pp. 3-17. Medline. 4. D. Thaci. Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects 1; all other biologics are recommended for second-line therapy 2-4. Currently, all biologic treatments for psoriasis, including anti-tumor necrosis factor therapies (anti-TNFs) and Stelara (ustekinumab) are recommended for second-line systemic therapy in Europe 2-4. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Article September 2004 British Journal of Dermatology. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151 Suppl 69:3-17. Biologic agents ...
Biological therapy is a treatment that uses your bodys immune system to fight cancer cells rather than attacking those cells directly. For carefully selected people, biological therapy may target cancer cells to avoid damage to normal cells, prevent or slow tumor growth, and prevent the spread of cancer cells. Although it can have side effects, typically this type of therapy is less invasive and less toxic than conventional cancer treatments are. Biological therapy for cancer includes immunotherapy, targeted therapy and therapy that inhibits the growth of blood vessels (anti-angiogenesis).
Bladder Cancer Biological Therapy India,Cost Biological Therapy India, Bladder Cancer In India Offers Info On Cost Bladder Cancer Surgery India, Bladder Cancer Treatment Hospital Mumbai India, Bladder Cancer Surgeons India Mumbai Bangalore, Bladder Cancer Center India, Bladder Cancer Doctors India
Biological therapy is used treat certain types of non-Hodgkin lymphoma. Learn how and when biological therapy is used and side effects of biological therapy.
FMT as a treatment modality has also been tested in a range of other diseases, such as inflammatory bowel disease (IBD), irritable bowel syndrome, obesity and metabolic syndrome, as well as neurological and psychological disorders, although most reports of the latter category are merely anecdotal. Yet, the results so far are not convincing. Reports about using FMT to treat IBD patients show considerable heterogeneity in terms of clinical effect (Moayyedi et al, 2015), whereas efficacy in patients with metabolic syndrome was transient. Insulin resistance improved 6 weeks after the FMT, but at 12 weeks, no significant effect was observed anymore on metabolic parameters and fecal microbiota composition (Vrieze et al, 2012).. The reason why FMT has such variable efficacy is probably due to the stability and resilience of the gut microbiota. CDI patients who have been treated multiple times with antibiotics have most of their bacterial diversity wiped out; FMT effectively repopulates this vacated ...
Clin Gastroenterol Hepatol. 2011 Dec;9(12):1044-9. doi: 10.1016/j.cgh.2011.08.014. Epub 2011 Aug 24. Research Support, N.I.H., Extramural; Research Support, Non-U.S. Govt; Review
Key takeaways from Randi Lundbergs review of the pros and cons of using antibiotic-treated or germ-free mice in fecal microbiota transplant studies.
Fecal microbiota transplantation is reportedly the most effective therapy for relapsing Clostridium Difficile infection and a potential therapeutic option for many diseases. It also poses important ethical concerns. This study is an attempt to assess clinicians perception and attitudes towards ethical and social challenges raised by fecal microbiota transplantation. A questionnaire was developed which consisted of 20 items: four items covered general aspects, nine were about ethical aspects such as informed consent and privacy issues, four concerned social and regulatory issues, (...) and three were about an FMT bank. This was distributed to participants at the Second China gastroenterology and FMT conference in May 2015. Basic descriptive statistical analyses and simple comparative statistical tests were performed. Nearly three quarters of the 100 respondents were gastro-enterologist physicians. 89% of all respondents believed FMT is a promising treatment modality for some diseases and 88% of ...
The high concentration of bacteria may be due to the fact that cats are, as you know, obligate carnivores. They have to eat the flesh of prey. The short intestinal tract of the cat would also seem to make it more important to have more bacteria in the gut. As consequence, some scientists think that if a cat is fed a high-protein, low carbohydrate diet matching the diet of the wild cat they are less likely to develop IBD.. The fact of the matter is that if scientists believe that bacteria in the gut plays a role in IBD then I would suggest that FMT is an ideal candidate has a form of treatment for this illness because FMT would replace, wholesale, the bad bacteria in the intestinal tract of the cat with the faecal bacteria of a healthy cat.. As for humans, FMT as a treatment for the management of IBD has been proved successful in studies. The success rate was high. In the 17 patients in whom it was reported, 13/17 ceased IBD medications within 6 weeks. All experienced symptom reduction or ...
Introduction. There is a growing body of evidence highlighting the possible interactions between the microbiota and cancer. However, little is known about the consequence on the microbiota of the intensive chemotherapy in patients with AML. Indeed, intensive treatments of AML are known to negatively impact gut microbiota composition; it is measured by a deep shutdown of diversity indices (eg. Simpson), also called dysbiosis. Decrease in microbiota diversity may impact the immune system and may have consequences on the outcome of AML patients. Therefore, development of strategies to manipulate the gut microbiota may minimize treatment-related complications and potentially improve outcomes. With this background, we developed a single arm prospective phase I/II multicenter trial (ClinicalTrials.gov Identifier: NCT02928523) aiming to evaluate use of auto-FMT in AML patients treated with intensive chemotherapy and antibiotics. Patients and methods. For this purpose, at the time of admission and AML ...
A 32-year-old Chinese man developed severe enterocolonic CD where he was hospitalized in 2012 for progressive abdominal pain, bloody and purulent diarrhea and high fever of 38 °C-39.5 °C. He was diagnosed in 2010 and managed his disease through daily intravenous medicines. A CT Scan showed an abdominal mass of size 14 cm × 8 cm × 10 cm. His sigmoid colon was severely inflamed and he was given intravenous antiobiotics for 10 days but frequently experienced fever and abdominal pain; plus, the abdominal mass size was unchanged. After the patient expressed interest in a clinical trial, various tests were conducted and the donor found was his 10-year-old, healthy daughter. A week after FMT, his previous symptoms were dramatically alleviated and the size of inflamed mass was reduced. Additionally, the CDAI score was reduced to 228. He had a severe cold in the whole third week after he was discharged with clinical improvement. At one month of follow-up after FMT, his CDAI score was further reduced ...
A 32-year-old Chinese man developed severe enterocolonic CD where he was hospitalized in 2012 for progressive abdominal pain, bloody and purulent diarrhea and high fever of 38 °C-39.5 °C. He was diagnosed in 2010 and managed his disease through daily intravenous medicines. A CT Scan showed an abdominal mass of size 14 cm × 8 cm × 10 cm. His sigmoid colon was severely inflamed and he was given intravenous antiobiotics for 10 days but frequently experienced fever and abdominal pain; plus, the abdominal mass size was unchanged. After the patient expressed interest in a clinical trial, various tests were conducted and the donor found was his 10-year-old, healthy daughter. A week after FMT, his previous symptoms were dramatically alleviated and the size of inflamed mass was reduced. Additionally, the CDAI score was reduced to 228. He had a severe cold in the whole third week after he was discharged with clinical improvement. At one month of follow-up after FMT, his CDAI score was further reduced ...
Key Points. Bacterial diversity was restored after FMT with oral frozen capsules, with improvement of diarrhea.Oral FMT for steroid-refractory acute gGVHD is f
Professor Borody is most famous for his ground-breaking work developing the triple therapy cure for peptic ulcers in 1987, which has saved hundreds of thousands…
FMT induces remission in a significantly greater percentage of patients with active UC than placebo, with no difference in adverse events. Fecal donor and time of UC appear to affect outcomes. ClinicalTrials.gov Number: NCT01545908.
Gastroenterology & Hepatology. January 2015, Volume 11, Issue 1. Woo Jung Lee, MD, Lakshmi D. N. Lattimer, MD, Sindu Stephen, MD, Marie L. Borum, MD, and David B. Doman, MD. Dr Lee and Dr Lattimer are gastroenterology fellows in the Division of Gastroenterology and Liver Diseases at George Washington University Medical Center and are affiliated with Medical Faculty Associates, both in Washington, DC. Dr Stephen is a gastroenterologist in Silver Spring, Maryland. Dr Borum is a professor of medicine at George Washington University School of Medicine in Washington, DC and the director of the Division of Gastroenterology and Liver Diseases at George Washington University Medical Center; she is also affiliated with Medical Faculty Associates. Dr Doman is a clinical professor of medicine at George Washington University School of Medicine.. Address correspondence to: Dr David B. Doman, 12012 Veirs Mill Road, Silver Spring, MD 20906, Tel: 301-942-3550, E-mail: [email protected] Abstract: The symbiotic ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Excision BioTherapeutics, a life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by neurotropic viruses, recently announced it has completed a $10 million seed round of financing, led by ARTIS Ventures. The investment will enable the company to enter into human clinical trials with its HIV-1 targeted CRISPR platform, giving Excision BioTherapeutics the first effort to fully remove/excise the HIV-1 genome from all human cells and tissues. In addition, Excision BioTherapeutics is extending this approach to other viruses by targeting their genetic elements, and eliminating them permanently from the patient. Regarding this development, Thomas Malcolm, Ph.D, Excision BioTherapeutics founder, president and CEO, stated Excisions mission has always been to advance gene editing therapeutics into safe and efficacious medicines that will eradicate or disrupt viral genes in human patients. The ...
Biological therapy (also called immunotherapy, biological response modifier therapy, or biotherapy) uses the bodys immune system to fight cancer. The cells, antibodies, and organs of the immune system work to protect and defend the body against foreign invaders, such as bacteria or viruses. Doctors and researchers have found that the immune system might also be able to both determine the difference between healthy cells and cancer cells in the body, and to eliminate the cancer cells. (By itself, the immune system is not always good at destroying cancer cells; if it were, people would not get cancer.). Biological therapies are designed to boost the immune system, either directly or indirectly, by assisting in the following:. ...
Kaltsonoudis et al.9 conducted a prospective study in 77 patients with inflammatory rheumatic disease (36 patients with rheumatoid arthritis, 24 patients with psoriatic arthritis and 17 patients with ankylosing spondylitis) who began with anti-TNFα (infliximab, adalimumab, etanercept). All underwent a complete neurological examination, nuclear magnetic resonance of the brain and the entire spine, and a neurophysiology study before and more than 18 months after starting the biological therapy. In the initial scrutiny, they detected lesions compatible with demyelinating disease in magnetic resonance in 2 patients and, thus, decided against the biological treatment. At the end of the study, 4% of the patients (3/75) showed evidence of neurological involvement: peripheral demyelinating neuropathy (2 patients) and optic neuritis. In each case, the biological therapy was interrupted and the neurological disease was treated. The neurological symptoms remitted in all the patients.9 The authors stress ...
Patients with inflammatory bowel disease who required abdominal surgery while on biologics did not have more postoperative complications than those whose biologic regimens were interrupted.13-15. The first study of patients with psoriasis or psoriatic arthritis on biologics enrolled 42 patients undergoing 77 different procedures.16 While patients who continued biologic therapy did not have higher rates of postoperative complications, those who did interrupt treatment found their underlying disease worsened. Most rheumatology associations recommend interrupting biologic therapy for at least 4 half-lives before scheduled major surgery; that criterion would involve going 4 to 6 weeks without infliximab, 6 to 8 weeks off adalimumab, 2 to 3 weeks off etanercept, and 12 to 25 weeks off ustekinumab before operations.17-19 The evidence supporting that recommendation, however, is weak; in fact, it is supported only by expert opinion.. The 2013 consensus statement of the Spanish Academy of Dermatology and ...
Looking for information on Biologic Therapies for Aging Discs in Fairmont? We have compiled a list of businesses and services around Fairmont that should help you with your search. We hope this page helps you find information on Biologic Therapies for Aging Discs in Fairmont.
Looking for information on Biologic Therapies for Aging Discs in Bellaire? We have compiled a list of businesses and services around Bellaire that should help you with your search. We hope this page helps you find information on Biologic Therapies for Aging Discs in Bellaire.
Asthma is a chronic and heterogenic respiratory tract disorder with a high global prevalence. The underlying chronic inflammatory process and airway remodeling (AR) contribute to the symptomatology of the disease. The most severely ill asthma patients may now be treated using a variety of monoclonal antibodies aiming key inflammatory cytokines involved in asthma pathogenesis. Although clinical data shows much beneficial effects of biological therapies in terms of reduction of exacerbation rates, improvement of lung functions, asthma control and patients quality of life, little is known on the effects of these monoclonal antibodies on AR-a key clinical trait of long-term asthma management. In this review, the authors summarize the data on the proven effects of monoclonal antibodies in asthma on AR. To date, in terms of reversing AR, the mostly studied was omalizumab. However, some studies also addressed this clinical issue in context of other severe asthma biological therapies (mepolizumab, benralizumab
Global Cancer Biologic Therapy Market- Forecast to 2021 The report firstly introduced Global Cancer Biologic Therapy Market including classification, appli
Biological therapy may be used to treat chronic myelogenous leukemia in the chronic or accelerated phase. Learn about biological therapy for CML.
Phage therapy or viral phage therapy is the therapeutic use of bacteriophages to treat pathogenic bacterial infections. Phage therapy has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture. If the target host of a phage therapy treatment is not an animal, the term biocontrol (as in phage-mediated biocontrol of bacteria) is usually employed, rather than phage therapy. Bacteriophages are much more specific than antibiotics. They are typically harmless not only to the host organism, but also to other beneficial bacteria, such as the gut flora, reducing the chances of opportunistic infections. They have a high therapeutic index, that is, phage therapy would be expected to give rise to few side effects. Because phages replicate in vivo, a smaller effective dose can be used. On the other hand, this specificity is also a disadvantage: a phage will only kill a bacterium if it is a match to the specific strain. Consequently, phage mixtures are ...
...FORT WORTH Texas June 7 2011 /- Healthpoint Biotherape...The presentations will include updates on the Companys ongoing commer... About Healthpoint Biotherapeutics ...Healthpoint Biotherapeutics is a biopharmaceutical company focused on ...,Healthpoint,Biotherapeutics,to,Present,at,Upcoming,Investment,Conferences,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Title: Phage Therapy in Clinical Practice: Treatment of Human Infections. VOLUME: 11 ISSUE: 1. Author(s):Elizabeth Kutter, Daniel De Vos, Guram Gvasalia, Zemphira Alavidze, Lasha Gogokhia, Sarah Kuhl and Stephen T. Abedon. Affiliation:Lab 1, The Evergreen State College, Olympia, WA 98505, USA.. Keywords:Bacteriophages, burn care, Eliava Institute, Hirszfeld Institute, intestiphage, osteomyelitis treatment, phage therapy, purulent infections, pyophage, wound care. Abstract: Phage therapy is the application of bacteria-specific viruses with the goal of reducing or eliminating pathogenic or nuisance bacteria. While phage therapy has become a broadly relevant technology, including veterinary, agricultural, and food microbiology applications, it is for the treatment or prevention of human infections that phage therapy first caught the worlds imagination - see, especially, Arrowsmith by Sinclair Lewis (1925) - and which today is the primary motivator of the field. Nonetheless, though the first human ...
Bacteriotherapy is the use of transplanted bacteria inside of an organism. Fecal bacteriotherapy works due to bacterial interference, the process by which bacteria displace pathogens. Bioremediation Biodegradation Microbial biodegradation van Nood, E; Vrieze, A; Nieuwdorp, M; et al. (January 2013). Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. N. Engl. J. Med. 368 (5): 407-15. doi:10.1056/NEJMoa1205037. PMID 23323867. Huovinen, Pentti (18 August 2001). Bacteriotherapy: the time has come. British Medical Journal. BMJ Group. 323 (7309): 353-354. doi:10.1136/bmj.323.7309.353. PMC 1120965 . PMID 11509411 ...
Fecal bacteriotherapy Fecal microbiota transplantation (FMT) also known as a stool transplant is the process of transplantation of fecal bacteria...
The scientific literature shows a renewed interest in phage therapy. Part of this interest stems from a series of spectacular experiments conducted with phage lysins (31, 37, 44), another part comes from a number of recent animal experiments with viable phage particles as antibacterial agents (8, 11, 14, 28, 30, 32, 49, 54), and a further part derives from historical reviews of the Soviet experience with phage therapy (4, 10, 12, 18, 48, 49, 50). It is currently difficult to critically assess the potential of the clinical trials conducted in the former Soviet Union. The trials were mainly published in Russian, most of the trials were uncontrolled, and the therapeutic phages were not described in published reports. With the present study, we wanted to address some of the basic preclinical problems of phage therapy in the context of E. coli diarrhea. We have chosen this example because a substantial body of knowledge has been accumulated on E. coli and its phages; the pathogenic target bacteria ...
This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the worlds 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the worlds 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of ...
Rectal bacteriotherapy, fecal microbiota transplantation or oral vancomycin treatment of recurrent Clostridium difficile infections: A randomized controlled trial. ...
Our Biologic Therapy Program focuses on the treatment of advanced melanoma and kidney cancer. Physicians, including Drs. Michael Atkins, David McDermott, James Mier, Rupal Bhatt, and Dan Cho, investigate and use biologic agents, such as cytokines and vaccines, to treat solid tumors in patients with metastatic melanoma and kidney carcinoma.
Title:Recent Advances in Probiotics as Live Biotherapeutics Against Gastrointestinal Diseases. VOLUME: 24 ISSUE: 27. Author(s):Rohini Krishna Kota, Ranga Rao Ambati*, Aswani Kumar Y.V.V., Krupanidhi Srirama and Prakash Narayana Reddy*. Affiliation:Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, Department of Biotechnology, Acharya Nagarjuna University Nagarjuna Nagar, Guntur- 522510, Andhra Pradesh, Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh. Keywords:Gastrointestinal diseases, therapy, probiotics, biotherapeutics, Fecal Microbial Transplants (FMTs), Gut microbiota ...
BETHESDA, MD, January 18, 2017 - Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (NW Bio), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will present at the Phacilitate Immunotherapy World Conference on Thursday, January 19, 2017, at the Hyatt Regency Hotel in Miami, Florida.. Dr. Bosch will chair the session entitled New Therapeutic Approaches - Expanding the Reach of Cancer Immunotherapy to All Patients In Need of Better Treatments, taking place from 4:30 p.m. to 5:35 p.m. on Thursday, January 19, and will make a presentation on the same subject. There will not be a webcast. The presentation was originally scheduled to be made by Ms. Linda Powers, CEO of NW Bio, but she was unable to do so due to illness.. The annual Phacilitate Immunotherapy World Forum is one of the worlds largest and fastest growing senior-level immuno-oncology ...
Funding Enables Existing Clinical Trials to Proceed as Company Joins Global Response with COVID-19 Program. PITTSBURGH - May 7, 2020 - Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, has received a $4 Million grant from the Commonwealth of Pennsylvania to continue clinical trials of its lead product candidate, ST266, in a wide range of diseases, including multiple ophthalmic indications. The funding will enable Noveome to shift its existing resources to support the companys recently launched COVID-19 program evaluating ST266 as a treatment for the cytokine storm-the severe inflammatory response often observed in COVID-19 infections.. While researchers around the world race to deliver a vaccine that will address this COVID-19 pandemic head on, we need a range of new therapeutics and diagnostics to stem the tide. This very timely funding will ...
3 Cases Substantially Completed, 4th Case Pending Completion, No Monetary Damages Contemplated. Bethesda, MD, October 24, 2017 - Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (NW Bio), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Companys periodic filings.. All four of the lawsuits have been or are being resolved without any negative findings against the Company or its management, despite allegations of misconduct and misrepresentation, and resolved without any monetary damages. One of the cases was dismissed outright, in its entirety, by the court. Two further cases were settled after NW Bio announced the Nasdaq remediation plan on September 6, 2016 and agreed to take certain future actions to enhance its corporate governance practices. The fourth case is in the process of being settled on similar ...
Global Biotherapeutics Cell Line Development Market is registering a CAGR of 7.50% from 2015 to 2022, the global biotherapeutics cell line development market is anticipated to reach a value of US$100 mn by 2022.
Free Online Library: The Effect of Fecal Microbiota Transplantation on a Child with Tourette Syndrome.(Case Report) by Case Reports in Medicine; Health, general Antipsychotic agents Antipsychotic drugs Behavioral health care Behavioral medicine Microbiota (Symbiotic organisms) Nervous system diseases Care and treatment Tourette syndrome Tourettes syndrome
Therapeutic approaches to generalized pustular psoriasis and psoriatic arthritis are discussed separately. Data are limited on the efficacy of biologic agents other than infliximab for the treatment of erythrodermic psoriasis. Key words: drug therapy; psoriasis. Second-line systemic therapies for PPPP are the biologic agents, alefacept, adalimumab, etaner- cept, and infliximab (Fig 5). In other forms of psoriasis, the use of etanercept, as that of other biological therapies, has been published in an isolated way with satisfactory results. Keywords. Generalized pustular psoriasis-Von Zumbusch, Palmoplantar psoriasis, Hallopeau acropustulosis perstan, Erythrodermal psoriasis, Etanercept. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequencial use of infliximab and adalimumab. Biologic therapies, including tumor necrosis factor inhibitors, can be effective for severe ...
Omics group organizes Biotherapeutics national symposiums, conferences across the globe in association with popular Biotherapeutics associations and companies. OMICS group planned its conferences, and events in america, europe, middle east and asia pacific. locations which are popular with international conferences, symposiums and events are china, canada, dubai, uae, france, spain, india, australia, italy, germany, singapore, malaysia, brazil, south korea, san francisco, las vegas, san antonio, omaha, orlando, raleigh, santa clara, chicago, philadelphia, baltimore, united kingdom, valencia, dubai, beijing, hyderabad, bengaluru and mumbai
Pulsed Xenon Robotic Antibiotic™ Quickly Destroys Deadly Pathogens That Cause Hospital-Acquired Infections. DUBLIN, IRELAND and JOHANNESBURG, SOUTH AFRICA-(Marketwired - Sep 17, 2015) - Serenus Biotherapeutics (Serenus), which is bridging the divide between the worlds leading healthcare markets and the growing demand for access to innovative drugs and devices in the emerging nations of Africa, today said it had entered into an agreement with Xenex Disinfection Services to bring the Xenex pulsed xenon Full-Spectrum™ ultraviolet (UV) room disinfection system to Africa.. The Xenex Germ-Zapping Robot™ is the most advanced UV disinfection robot available and is used throughout hospitals, outpatient surgery centers and skilled nursing facilities in the United States, Canada and Europe. In a five minute disinfection cycle, the robot destroys contagious superbugs on surfaces through the use of high intensity pulsed xenon UV light. Designed for speed, effectiveness and ease of use, hospital ...
Cancer Monthly. Ovarian Cancer treatments. Biologic therapy. Chemotherapy. University of Queensland, Brisbane, Australia. Compare therapy differences, longest survival rates, toxicity, side effects, hospitals.
Cancer Monthly. Breast Cancer treatments. Biologic therapy. Chemotherapy. Jules Bordet Institute, Brussels, Belgium. Compare therapy differences, longest survival rates, toxicity, side effects, hospitals.
Fecal microbiota transplantation (FMT) has had a long history in medicine for treating a number of human diseases. As early as during the 4th century BC, FMT was used in China to treat patients with food poisoning and diarrhea. Over time, the method became obsolete, particularly after the realization that hygiene plays an important role in preventing infectious diseases. It was not until the late 1950s that FMT garnered interest again when the first reports about its use to treat fulminant enterocolitis appeared in the scientific literature. However, FMTs breakthrough as the method of choice for the treatment of persistent Clostridium difficile infection (CDI) came only after a double‐blind randomized trial (van Nood et al, 2013), which demonstrated 94% efficacy of FMT compared with 31% after conservative treatment with vancomycin. ...
The interactions between the composition of the microbiota and gut motility are bidirectional, which indicates that the microbiota play an important role in gut motor function and the gut motor function affects the diversity of microflora in the gastrointestinal tract [6]. Here, we found that the depletion of microbiota by antibiotics treatments was associated with gut motility, and its relationship might be related to 5-HT biosynthesis in the colon. And we also found that metabolism of bile acids was affected in antibiotic-treated mice, and the secondary bile acids was decreased in our study which has been demonstrated to be associated with 5-HT metabolism and gastrointestinal motility [13].. Several studies have focus on the interaction between the normal gut microbiota and gut motility. The dysfunction of gut motility has been considered to be one of the main pathophysiology in STC [31]. Recent years, fecal microbiota transplantation (FMT) has become a new therapy for functional ...
Clostridium difficile, commonly known as C. diff, affects nearly half a million Americans a year, and leads to several thousand fatalities, according to the CDC. This infection is difficult to treat, especially among those with an antibiotic-resistant strain, but Peter Moses, M.D., professor of medicine at the Larner College of Medicine and gastroenterologist at the UVM Medical Center, uses fecal microbiota transplantation (FMT) as a solution ...
TY - JOUR. T1 - Biological challenges of phage therapy and proposed solutions. T2 - a literature review. AU - Caflisch, Katherine M.. AU - Suh, Gina A.. AU - Patel, Robin. PY - 2019/12/2. Y1 - 2019/12/2. N2 - Introduction: In light of the emergence of antibiotic-resistant bacteria, phage (bacteriophage) therapy has been recognized as a potential alternative or addition to antibiotics in Western medicine for use in humans. Areas covered: This review assessed the scientific literature on phage therapy published between 1 January 2007 and 21 October 2019, with a focus on the successes and challenges of this prospective therapeutic. Expert opinion: Efficacy has been shown in animal models and experimental findings suggest promise for the safety of human phagotherapy. Significant challenges remain to be addressed prior to the standardization of phage therapy in the West, including the development of phage-resistant bacteria; the pharmacokinetic complexities of phage; and any potential human immune ...
Abstract. Background. Within seven days following peroral high dose infection with Toxoplasma gondii susceptible conventionally colonized mice develop acute ileitis due to an underlying T helper cell (Th) -1 type immunopathology. We here addressed whether mice harboring a human intestinal microbiota developed intestinal, extra-intestinal and systemic sequelae upon ileitis induction.. Methodology/Principal findings. Secondary abiotic mice were generated by broad-spectrum antibiotic treatment and associated with a complex human intestinal microbiota following peroral fecal microbiota transplantation. Within three weeks the human microbiota had stably established in the murine intestinal tract as assessed by quantitative cultural and culture-independent (i.e. molecular 16S rRNA based) methods. At day 7 post infection (p.i.) with 50 cysts of T. gondii strain ME49 by gavage human microbiota associated (hma) mice displayed severe clinical, macroscopic and microscopic sequelae indicating acute ileitis. ...
They proved this by fecal microbiota transplantation which involved taking a stool sample solution from the humans and administering it into the digestinal tract of mice. The human stool samples were taken before and after metformin treatment and the mice had been put on a high-calorie diet. The fecal transplant is thought to help pass good bacteria from a healthy person to someone who is unwell ...
The introduction of biologic therapies, which selectively target components of the immune system, has revolutionized the treatment of rheumatoid arthritis. Anti-TNF-alpha therapy (infliximab, etanercept and adalimumab) and B-cell-depleting agents, such as rituximab, are the most widely used agents. Increased experience of the use of biologic drugs in other immune-mediated inflammatory diseases has led to the application of biologic therapies in the treatment of primary systemic vasculitis. Conversely, the success of biological agents has improved understanding of the immunopathogenesis of vascular inflammation. The need for biologic agents arises from the failure of the current standard of care to maintain remission while limiting drug toxicity. Evidence for the efficacy of biologic agents does not match that of conventional immunosuppressants yet, but it is building rapidly. This paper reviews the current evidence for the standard of care of patients with vasculitis and the role of biologic therapy in
BACKGROUND: Axial spondyloarthropathy typically has its onset in early adulthood and can impact significantly on quality of life. In the UK, biologic anti-tumour necrosis factor therapy is recommended for patients who are unresponsive to non-steroidal anti-inflammatory drugs. There remain several unresolved issues about the long-term safety and quality of life outcomes of biologic treatment in axial spondyloarthropathy. Long-term real-world surveillance data are required to complement data from randomised controlled trials. METHODS/DESIGN: We are conducting a UK-wide prospective cohort study of patients with axial spondyloarthropathy who are naïve to biologic therapy at the time of recruitment. Those about to commence anti-tumour necrosis factor biologic therapy will enter a biologic sub-cohort with other patients assigned to a non-biologic sub-cohort. The primary objective is to determine whether the use of biologic therapy is associated with an increased risk of serious infection, while ...
Beyond its role in therapy, FMT is providing insights into the importance of intestinal microbiota in health and disease. As physicians and scientists, we live in exciting times! Bacteria are no longer viewed solely as pathogens, but also as key partners in the maintenance of health. It is conceivable that altering the microbiota in our gastrointestinal tract may either predispose us to disease or ameliorate conditions we already have. Faecal microbiota transplantation (FMT) has captured the attention of the lay press and professional journals since 1958, when faecal enema was reported to have cured four patients near death from severe Micrococcus pyogenes colitis.1. ...
SOUTH SAN FRANCISCO, Calif., July 16, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
Integrated BioTherapeutics (IBT) has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH. The company will receive $550,000 for work to take place over the next two years.. The award is entitled Development of Therapeutic Pan-Filovirus Macaque Monoclonal Antibodies and the principal investigator is Dr. Sven Enterlein, Assistant Director of Molecular Virology. Filoviruses, including the well known Ebola Virus, are classified as Category A Priority Pathogens by NIAID. No vaccines or effective therapies are currently available for use in humans against these viruses. In this grant, IBT will combine its proprietary engineered filovirus antigens with Trelliss CellSpot(TM) technology in order to isolate non-human primate monoclonal antibodies that provide broad protective efficacy. CellSpot(TM) is a powerful platform developed and patented by Trellis Bioscience, LLC. (www.trellisbio.com) ...
Investor info Aeglea BioTherapeutics: researching enzyme treatment and therapeutic human engineered enzymes to help treat cancer and rare genetic disease.
AGLE: Get the latest Aeglea BioTherapeutics stock price and detailed information including AGLE news, historical charts and realtime prices.
The first therapeutic usage of phage was in 1919, to treat a child with severe dysentery. In a classic case of old-school science, the lead researchers (which included dHerelle) drank portions of the bacteriophage preparation the day before treating the child, to check the treatments safety in humans. The researchers didnt keel over, the child fully recovered within a few days, and further tests on other patients confirmed the result. In the 1930s and 1940s, bacteriophage preparations were developed and sold by major companies such as LOréal and the Eli Lilly Company. The development and mass production of antibiotics in the late 1940s halted research into phage therapy in the West, due to the efficacy of antibiotics. Research continued in the Soviet Union. Hundreds of studies were made on phage therapy, with the the largest carried out in Tbilisi in 1963-64, involving 30,000 children [1]. This study focused on the use of phage as a weekly-administered prophylactic against Shigella. The ...
Using an experimental treatment that involves the use of bacteriophages, or viruses that target bacteria specifically, the team has successfully treated Tom Patterson, PhD, a psychiatric professor at the UCSD School of Medicine.. In 2015, Patterson contracted what appeared at the time to be pancreatitis, but it was soon discovered by a team of specialist doctors in Frankfurt, Germany, that Patterson had contracted an extremely rare, dangerous, virulent, and antimicrobial-resistant strain of the Acinetobacter baumannii pathogen.. After attempting to treat Pattersons condition with an increasingly dangerous cocktail of potent and hazardous antibiotics, Pattersons health began to fail rapidly, at which point he was airlifted to Thornton Hospital, at UCSD. With doctors unable to stop the spread of Acinetobacter baumannii superbug, Patterson was eventually placed into a medical coma in January 2016.. In March of the same year, a research team began treating Patterson with a unique phage therapy ...
Cytokines such as tumor necrosis factor (TNF) are expressed at high levels in rheumatoid joint tissue, where they contribute significantly to inflammation and articular destruction. TNF was the first cytokine to be fully validated as a therapeutic target for rheumatoid arthritis (RA). In nearly a decade since anti-TNF agents-such as infliximab, etanercept and adalimumab-were launched as the first biologic therapies to be licensed for RA, much has been learnt about how and when in the disease course this class of drug can be used to achieve optimal therapeutic benefit. Other cytokine targets, such as interleukin (IL)-6 or IL-1, have also been validated and several are in the process of being tested. However, TNF is likely to remain the preferred target of first-line biologic therapy for the foreseeable future as, in populations with active RA despite ongoing, nonbiologic, DMARD therapy, biologic inhibition of either IL-6 or IL-1 demonstrates no obviously superior outcomes to TNF blockade. Furthermore,
Most authorities recommend starting biological agents upon failure of at least one disease-modifying agent in patients with rheumatoid arthritis. However, owing to the absence of head-to-head studies, there is little guidance about which biological to select. Still, the practicing clinician has to decide. This review explores the application of published evidence to practice, discussing the goals of treatment, the (in) ability to predict individual responses to therapy, and the potential value of indirect comparisons. We suggest that cycling of biological agents, until remission is achieved or until the most effective agent for that individual patient is determined, deserves consideration in the current stage of knowledge.
Questions addressing in whom and when to perform LTI screening, and chemoprophylaxis regimens and duration, were answered correctly by 93 and 94% of respondents, respectively. In contrast, questions concerning the action to be taken in the case of negative TT and the tests that should be requested for screening were only answered correctly by 25 and 36% of respondents, respectively.. Discussion. This survey of a wide range of medical specialists involved in the administration of biologics revealed a low degree of adherence to the recommendations of the Spanish Consensus Document on the Prevention and Treatment of Tuberculosis in Patients who are Candidates for Biological Treatment.16 Only 56% of respondents showed acceptable adherence to the recommendations. In 98% of cases, LTI screening was performed in the respondents own hospital, and this was the only variable associated with better adherence to the consensus. The percentage of respondents who conduct the screening themselves and their ...
Results We included 223 RA patients (79.4% of female, mean ± SD disease duration of 8.9±8.6 years). The mean age was 54±10.9 years, 70.8% rheumatoid factor (RF) positive, 84.4% anti-citrullinated protein antibody (ACPA) positive and 68.1% had radiographic damages. The mean DAS 28 was 5.5±2.6; 71% of patients received corticosteroids (mean 7mg per day of equivalent prednisone) and 63% methotrexate (mean 17.8mg per week). No patient had pain or other sinus or dental symptoms. Before biologic agent initiation, systematic dental and sinus screening revealed an oral infection in 31.5% of patients (dental: 20.2% and sinus: 14.8%). In univariate analysis, active smoking was associated with a higher risk of oral infection (OR=2.16 [1.02-4.57], p=0.038) and methotrexate with a lower rate (OR=0.43 [0.23-0.81], p=0.006). Corticosteroid, disease duration, DAS 28, RF, ACPA and structural damages were not associated with oral infection. No significant association was confirmed with oral infection using ...
ECCO - European Crohn´s and Colitis Organisation. The European Crohn\s and Colitis Organisation is a highly active non-profit association focusing on Inflammatory Bowel Diseases (IBD).
Objective: To survey the current status and problems of cooperation between clinics and hospitals in Okayama Prefecture, Japan for the treatment of rheumatoid arthritis (RA). Methods: We distributed a questionnaire to 300 of the 983 Okayama Prefecture clinics that had either an internal medicine or orthopedic surgery department, from December 2013 to February 2014. The questionnaire covered practice pattern for RA treatment in clinics, current status of the hospital and clinic cooperation, and acceptance of the biologic therapy. Results: One hundred clinics responded to the questionnaire. Seventy percent of the clinics reported making referrals to rheumatologists before the initiation of RA treatment, and half of the other 30% of the clinics administered methotrexate as the first-line treatment for RA by their own decision. Sixty-six clinics cooperated with flagship hospitals, conducting medical and laboratory examinations, providing prescriptions, and treating common diseases of patients. These ...
Results A total of 3880 patients (75.3% women) with a mean age of 51.3 years started non-biological DMARDs. After 5 years, 234 patients (6.0%) initiated biological DMARD therapy in 17.5±13.9 months. Differences in the socio demographic and pharmacological characteristics between the two groups of treatment are shown in the table 1. The use of glucocorticoids was associated with a greater risk of biological DMARD initiation (OR: 2.49; 95% CI: 1.658-3.732; p,0.001), while the use of methotrexate (OR: 0.04; 95% CI: 0.014-0.108; p,0.001) and chloroquine (OR: 0.13; 95% CI: 0.092-0.187; p,0.001) reduced the risk of initiation. ...
Objectives: A cohort of routine care RA patients in sustained remission had biological DMARD (bDMARDs) tapered according to a treatment guideline. We studied: the proportion of patients whose bDMARD could be successfully tapered or discontinued; unwanted consequences of tapering/discontinuation; and potential baseline predictors of successful tapering and discontinuation.. Methods: One-hundred-and-forty-three patients (91% receiving TNF inhibitor and 9% a non-TNF inhibitor) with sustained disease activity score (DAS28-CRP)⩽2.6 and no radiographic progression the previous year were included. bDMARD was reduced to two-thirds of standard dose at baseline, half after 16 weeks, and discontinued after 32 weeks. Patients who flared (defined as either DAS28-CRP ⩾ 2.6 and ΔDAS28-CRP ⩾ 1.2 from baseline, or erosive progression on X-ray and/or MRI) stopped tapering and were escalated to the previous dose level.. Results: One-hundred-and-forty-one patients completed 2-year follow-up. At 2 years, 87 ...
Palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP) are diseases affecting the hands and/or feet that can cause marked physical discomfort and functional disability. The tumor necrosis factor-alpha antagonists adalimumab, etanercept, and infliximab, the interleukin (IL)-17A inhibitors ixekizumab and secukinumab, and the IL-23 or IL-12/IL-23 inhibitors guselkumab and ustekinumab have been well studied for the treatment of moderate to severe plaque psoriasis. Less is known about the efficacy and safety of these agents for the treatment of PP (hyperkeratotic and pustular forms) and PPP. The aim of this review was to investigate the efficacy of biologic therapy for the treatment of hyperkeratotic PP, pustular PP, and PPP.A systematic search of the medical electronic databases (Medline, Embase, and Cochrane Library) was conducted to identify studies or case reports which both used biologic therapy for the treatment of hyperkeratotic PP, pustular PP, and PPP and reported treatment ...
The way the radiation therapy is given depends on the type and stage of the cancer being treated. External and internal radiation therapy are used to treat penile cancer.. Chemotherapy. Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly onto the skin (topical chemotherapy) or into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). The way the chemotherapy is given depends on the type and stage of the cancer being treated.. Topical chemotherapy may be used to treat stage 0 penile cancer.. See Drugs Approved for Penile Cancer for more information.. Biologic therapy. Biologic therapy is a ...
TY - JOUR. T1 - Pseudomonas aeruginosa: the potential to immunise against infection. AU - Sedlak-Weinstein, L.. AU - Kyd, Jennelle. AU - Foxwell, Ruth. PY - 2005. Y1 - 2005. M3 - Article. VL - 5. SP - 967. EP - 982. JO - Expert Opinions in Biological Therapies. JF - Expert Opinions in Biological Therapies. SN - 1471-2598. ER - ...
The availability of newer therapies has provided an opportunity to improve the management of patients with severe asthma. This program aims to ensure that clinicians are able to differentiate severe asthma from difficult-to-treat asthma so that patients who need these novel therapies are provided with them. This program will review the important role of phenotypes, endotypes, and biomarkers in severe asthma management, and the utility of common biomarkers as predictive markers. Following this program, clinicians will be able to utilize information from biomarker testing and clinical exam to select therapies that are appropriately individualized to specific patients, while also minimizing reliance on oral corticosteroids (OCS). Finally, adequate and personalized monitoring for response to therapy, adherence, patient satisfaction, and opportunities for optimizing therapy is critical. This program will review strategies to identify and address these care considerations, as well as what is known ...
This partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells. ...
Only recently have asthma strategies addressed biomarkers in asthma management, for example, as applied in the identification of severe asthmatics likely to respond to biologic therapy. Three biomarkers are readily available for clinical application in managing severe asthma including blood eosinophils, exhaled nitric oxide and serum IgE. While we have a limited number of biomarkers for clinical application, the available biomarkers have ushered in the era of personalized medicine for asthma. These three biomarkers are readily available for application in the clinic setting to select medications and to monitor response to treatment as well as medication adherence. These biomarkers can be used to modify the cost of uncontrolled asthma and also used to select those patients likely to respond to the available biologic therapies for severe asthma ...
Barbara J. Gitlitz is treating Laryngeal Cancer, Lung Cancer, Ovarian Cancer, Pericardial Mesothelioma , Pleural Mesothelioma, Testicular Mesothelioma To request an appointment with Barbara J. Gitlitz call us at (435) 200-5326.
Ixekizumab significantly improves symptoms of psoriatic arthritis in patients naive to prior biologic therapy and in patients who had failed prior to biologic therapy.
"Xolair - Biological Therapy". Drugdevelopment-technology.com. Leung DY, Sampson HA, Yunginger JW, et al. (2003). "Effect of ... Chang is a cofounder of Tanox, a biopharmaceutical company specialized in anti-IgE therapies for the treatment of allergic ... Chang TW, 2000, "The pharmacological basis of anti-IgE therapy." Nature Biotechnology, 18(2), 157-162. Chang TW and Shiung YY, ... anti-IgE therapy in patients with peanut allergy". N. Engl. J. Med. 348 (11): 986-93. doi:10.1056/NEJMoa022613. PMID 12637608. ...
Taylor RW (February 2005). "Gene therapy for the treatment of mitochondrial DNA disorders". Expert Opinion on Biological ... Presently, gene therapy and nutraceutical supplementation are popular areas of ongoing research. Bjelakovic et al. analyzed the ... An IVF technique known as mitochondrial donation or mitochondrial replacement therapy (MRT) results in offspring containing ... The Journal of Biological Chemistry. 281 (1): 374-82. doi:10.1074/jbc.M509730200. PMID 16263719. Jemt E, Farge G, Bäckström S, ...
Expert Opinion on Biological Therapy. 15 (8): 1155-72. doi:10.1517/14712598.2015.1051527. PMC 4883659. PMID 26027436. Loh QL, ... Biological scaffolds can be created from human donor tissue or from animals; however, animal tissue is often more popular since ... Series B, Biological Sciences. 362 (1484): 1505-12. doi:10.1098/rstb.2007.2131. PMC 2440411. PMID 17588875. Gandaglia A, Bagno ... Studies led by Dohmen, Konertz, and colleagues in Berlin, Germany involved the implantation of a biological pig valve in 50 ...
Goldstein, A.L. and Garaci, E., Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious ... Expert Opinion on Biological Therapy. 18 (sup1): 77-83. doi:10.1080/14712598.2018.1494717. ISSN 1744-7682. OCLC 768086347. PMID ... Expert Opinion on Biological Therapy. 18 (sup1): 9-11. doi:10.1080/14712598.2018.1484447. ISSN 1471-2598. OCLC 644930062. PMID ... Goldstein's research has helped define the role of biological response modifiers in health and disease, and has led to the ...
Other treatment options include biological therapies such as everolimus, torisel, nexavar, sutent, and axitinib, the use of ... Treatment may include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy. Kidney cancer newly ... "Biological therapy for kidney cancer". 2017-08-30. Jonasch, Eric; Messner, Carolyn (August 2012). "CancerCare Connect - ... The utility of renal mass biopsy (RMB) lies in that it can confirm malignancy with reliability, can direct therapy based on ...
Triozzi, PL; Borden, EC (December 2011). "VB-111 for cancer". Expert Opinion on Biological Therapy. 11 (12): 1669-76. doi: ... Ofranergene obadenovec, also known as VB-111, is an anti-angiogenic gene therapy. The vector is a non-replicating adenovirus 5 ...
Expert Opinion on Biological Therapy. 7 (5): 713-26. doi:10.1517/14712598.7.5.713. PMID 17477808. S2CID 12725001. Pfeifer A, ... The CJD Therapy Advisory Group to the UK Health Departments advises that data are not sufficient to support claims that ... Series B, Biological Sciences. 356 (1406): 185-95. doi:10.1098/rstb.2000.0764. PMC 1088424. PMID 11260799. Ridley RM, Baker HF ... This research is unlikely to lead to a human therapy for many years. Both amphotericin B and doxorubicin have been investigated ...
Trobridge, Grant D. (November 2009). "Foamy virus vectors for gene transfer". Expert Opinion on Biological Therapy. 9 (11): ... it may be a better vector for gene therapy than other foamy viruses. The budding characteristic of EFV from the plasma membrane ...
Expert Opinion on Biological Therapy. 10 (2): 163-78. doi:10.1517/14712590903431022. PMC 2809805. PMID 19947897. "Anti-GD2 for ... It is given in patients who have completed induction therapy and consolidation therapy (autologous bone marrow transplant and ... external beam radiation therapy), as part of standard-of-care therapy for newly-diagnosed high-risk neuroblastoma. It is given ... Dinutuximab is used as post-consolidation therapy for children with high-risk neuroblastoma, in combination with granulocyte- ...
Expert Opinion on Biological Therapy. 20 (8): 831-836. doi:10.1080/14712598.2020.1767062. ISSN 1471-2598. PMID 32380868. S2CID ... a potential therapy agent for lung cancer". Cancer Gene Therapy. 17 (4): 256-65. doi:10.1038/cgt.2009.74. PMID 19893593. S2CID ... Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RC, Zhang X (July 2003). "Effective therapy of metastatic ovarian cancer with an ... Ilyinskaya GV, Mukhina EV, Soboleva AV, Matveeva OV, Chumakov PM (2018). "Oncolytic Sendai Virus Therapy of Canine Mast Cell ...
Expert Opinion on Biological Therapy. Informa UK Limited. 20 (9): 1061-1072. doi:10.1080/14712598.2020.1749259. ISSN 1471-2598 ... "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021. "Drug ... Clinical trial number NCT02028884 for "Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat ...
Expert Opinion on Biological Therapy. 8 (12): 1955-62. doi:10.1517/14728220802517901. PMID 18990082. S2CID 74736842. Kupchik YM ... Inhaled acetylcysteine has been used for mucolytic ("mucus-dissolving") therapy in addition to other therapies in respiratory ... Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (December 2008). "N-acetylcysteine for antioxidant therapy: pharmacology and ... Samuni Y, Goldstein S, Dean OM, Berk M (August 2013). "The chemistry and biological activities of N-acetylcysteine". Biochimica ...
Expert Opinion on Biological Therapy. 7 (5): 599-615. doi:10.1517/14712598.7.5.599. PMID 17477799. S2CID 43003664. Watzl C ( ... preventing this therapy from being used in combination with monoclonal antibody therapies. NK-92 cells were derived from a ... Wu S, Fu T, Jiang Y, Shao Z (2020). "Natural killer cells in cancer biology and therapy". Molecular Cancer. 19 (1): 120. doi: ... Smyth MJ, Hayakawa Y, Takeda K, Yagita H (November 2002). "New aspects of natural-killer-cell surveillance and therapy of ...
Pattle, SB; Farrell, PJ (November 2006). "The role of Epstein-Barr virus in cancer". Expert Opinion on Biological Therapy. 6 ( ... The Merck manual of diagnosis and therapy (18th ed.). Whitehouse Station (NJ): Merck Research Laboratories. ISBN 978-0-911910- ...
Expert Opinion on Biological Therapy. 14 (7): 905-916. doi:10.1517/14712598.2014.900537. PMID 24673175. Schmidt-Wolf, IG; Finke ... These properties, inter alia, rendered CIK cells attractive as a potential therapy for cancer and viral infections. A new ... Molecular Therapy. 21 (12): 2268-77. doi:10.1038/mt.2013.192. PMC 3863798. PMID 23985696. Tettamanti, Sarah; Marin, Virna; ...
Expert Opinion on Biological Therapy. 8 (8): 1187-99. doi:10.1517/14712598.8.8.1187. PMID 18613770. Waknine Y (December 4, 2009 ...
Expert Opinion on Biological Therapy. 14 (6): 831-9. doi:10.1517/14712598.2014.898749. PMID 24655038. S2CID 33654830. "Stem ... January 2007). "Isolation of amniotic stem cell lines with potential for therapy". Nature Biotechnology. 25 (1): 100-6. doi: ... sidestep the donor/recipient issue which has so far stymied all attempts to use donor-derived stem cells in therapies. ...
Lima XT, Abuabara K, Kimball AB, Lima HC (August 2009). "Briakinumab". Expert Opinion on Biological Therapy. 9 (8): 1107-13. ...
... an overview of their potential in cell-based therapy". Expert Opinion on Biological Therapy. 15 (9): 1293-306. doi:10.1517/ ... Designed to be applied broadly, the original definition includes cell and stem cell therapies, gene therapy, tissue engineering ... had the potential to develop into a new kind of regenerative therapy. Explaining the new class of therapies that such cells ... The first cell therapies were intended to slow the aging process. This began in the 1930s with Paul Niehans, a Swiss doctor who ...
... or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies ... International Society for Biological Therapy of Cancer Cancer Research Institute Annual International Cancer Immunotherapy ... Masihi KN (July 2001). "Fighting infection using immunomodulatory agents". Expert Opinion on Biological Therapy. 1 (4): 641-53 ... Immune tolerance therapies seek to reset the immune system so that the body stops mistakenly attacking its own organs or cells ...
"Advances in adenovirus-mediated p53 cancer gene therapy". Expert Opinion on Biological Therapy. 13 (11): 1569-1583. doi:10.1517 ... Immune gene therapy is a targeted approach to cancer therapy where actual immune cells of the patient and their genes are ... In the past few decades, gene therapy has emerged as a targeted way to treat cancer. Gene therapy introduces foreign genetic ... In regards to gene therapy, IL2 can be used to increase replication and dispersing of CAR-T cells throughout the body. There is ...
Expert Opinion on Biological Therapy. 8 (9): 1407-15. doi:10.1517/14712598.8.9.1407. PMID 18694358. S2CID 73237824. Schubert- ... The drug is used for the treatment of malignant ascites in people with EpCAM-positive cancer if a standard therapy is not ... Fresenius concentrates biotechnology activities on antibody and innovative cell therapies". Fresenius SE. Archived from the ...
Expert Opinion on Biological Therapy. 12 (1): 7-22. doi:10.1517/14712598.2012.632765. PMID 22171664. S2CID 39322743. Esposito M ... Reynolds G (2011-01-26). "Phys Ed: Does Platelet-Rich Plasma Therapy Really Work?". New York Times. Storrs C (2009-12-18). "Is ... In 2019, Health Canada stated that most autologous cell therapies have little evidence showing they work and can pose risks, ... Kolata G (2010-01-12). "Popular Blood Therapy May Not Work". New York Times. Schwarz A (2009-02-16). "A Promising Treatment for ...
Expert Opinion on Biological Therapy. 9 (4): 493-506. doi:10.1517/14712590902870386. PMC 3049225. PMID 19344285. Lee, YJ; Yi, H ...
Expert Opinion on Biological Therapy. 16 (4): 567-72. doi:10.1517/14712598.2016.1158807. PMID 26914639. S2CID 24706213. ... As of 2016 it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's. ... According to data of one meta-analysis efficacy of Etrolizumab is comparable with conventional therapies such as Infliximab ...
Cunningham AL (2016). "The herpes zoster subunit vaccine". Expert Opinion on Biological Therapy. 16 (2): 265-71. doi:10.1517/ ... It is likely that incidence rate will change in the future, due to the aging of the population, changes in therapy for ... The drugs are used both for prevention (for example in people with HIV/AIDS) and as therapy during the acute phase. ... Furuta Y, Ohtani F, Mesuda Y, Fukuda S, Inuyama Y (2000). "Early diagnosis of zoster sine herpete and antiviral therapy for the ...
Expert Opinion on Biological Therapy. 10 (7): 1077-87. doi:10.1517/14712598.2010.487060. PMID 20455790. S2CID 28427056.. ...
Expert Opinion on Biological Therapy. 14 (4): 503-13. doi:10.1517/14712598.2014.887676. PMID 24579720. Costelloe L, Jones J, ... Knier B, Hemmer B, Korn T (April 2014). "Novel monoclonal antibodies for therapy of multiple sclerosis". ... suggest that the uncovering of a new molecular target for monoclonal antibody therapy would be welcomed in the research for an ... notably through immunotherapy such as monoclonal antibody therapy which is known to be efficient against autoimmune diseases. ...
Expert Opinion on Biological Therapy. 2 (2): 211-8. doi:10.1517/14712598.2.2.211. PMID 11849120. S2CID 28408255. Wieman TJ, ...
Mantesso, A.; Sharpe, P. (2009). "Dental stem cells for tooth regeneration and repair". Expert Opinion on Biological Therapy. 9 ... 2008 DPSC 1st animal studies begin for heart therapies. 2008 IDPSC 1st animal study began for muscular dystrophy therapies. ... Expert Opinion on Biological Therapy. 18 (2): 187-196. doi:10.1080/14712598.2018.1402004. PMID 29110535. Song, D.; Xu, P.; Liu ... Therapy. 8 (1): 198. doi:10.1186/s13287-017-0648-5. PMC 5622448. PMID 28962585. Yao, S.; Tan, L.; Chen, H.; Huang, X.; Zhao, W ...
"Brazilian Journal of Medical and Biological Research = Revista Brasileira de Pesquisas Medicas e Biologicas. 39 (8): 1065-70. ... Patients had to have CD4 cell counts less than 200 and at least 3 months of AZT therapy before the trials. 1156 patients with a ... It is normally used as one of the three drugs in a triple-combination therapy for the HIV virus.[1] ... is a protease inhibitor used as a component of highly active antiretroviral therapy to treat HIV/AIDS. It is soluble white ...
Examples include immuno-augmentation therapy, shark cartilage, bioresonance therapy, oxygen and ozone therapies, and insulin ... that has a biological or psychological effect on a patient may also have potential to possess dangerous biological or ... Prevalence of use of specific therapies. The most common CAM therapies used in the US in 2002 were prayer (45%), herbalism (19 ... The label "unproven" is inappropriate for such therapies; it is time to assert that many alternative cancer therapies have been ...
"β-Catenin". Sino Biological Inc.: Biological Solution Specialist. Reynolds AB (June 2011). "Epithelial organization: new ... Recently, there have been a number of studies in the lab and in the clinic investigating new possible therapies for cancers ... Coluzzi F, Mandatori I, Mattia C (September 2011). "Emerging therapies in metastatic bone pain". Expert Opin Emerg Drugs. 16 (3 ...
Berkowitz, S.A., Philo, J.S. Monitoring the Homogeneity of Adenovirus Preparations (a Gene Therapy Delivery System) Using ... Centrifugation in biological researchEdit. MicrocentrifugesEdit. Microcentrifuges are used to process small volumes of ... Ultracentrifugation makes use of high centrifugal force for studying properties of biological particles. Compared to ... biological molecules, cells, or nuclei. Microcentrifuge tubes generally hold 0.5 - 2.0 mL of liquid, and are spun at maximum ...
... s are now produced synthetically and used as drugs in cancer therapy and as immunosuppressive drugs. These ... "Synthesis and biological evaluation of Vinca alkaloids and phomopsin hybrids". Journal of Medicinal Chemistry. 52 (1): 134-142 ...
A Vital Legacy: Biological and Environmental Research in the Atomic Age, U.S. Department of Energy, The Office of Biological ... PET has an expanding role as a method to assess the response to therapy, in particular, cancer therapy,[57] where the risk to ... Psychiatry: Numerous compounds that bind selectively to neuroreceptors of interest in biological psychiatry have been ... Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy. Boca Raton: CRC Press. pp. 156-159.. ...
"Experimental therapies: growing interest in the use of whole blood or plasma from recovered Ebola patients (convalescent ... May 2002). "Hemorrhagic fever viruses as biological weapons: medical and public health management". Journal of the American ... It has the potential to be weaponised for use in biological warfare,[226][227] and was investigated by Biopreparat for such use ... This includes either oral rehydration therapy (drinking slightly sweetened and salty water) or giving intravenous fluids as ...
These analyses may also prove useful in determining therapy and monitoring its efficacy."[1] ... Neural network (biological). *Detection theory. *Intraoperative neurophysiological monitoring. *Neurochip. *Neurodegeneration. ...
"Arthritis Research & Therapy. 8 (3): R55. PMC 1526645. . PMID 16542493. doi:10.1186/ar1920. الوسيط ,السنة=. تم تجاهله (مساعدة ... a newly discovered member of the leucine-rich repeat protein family". The Journal of Biological Chemistry. 276 (15): 12212-21. ... a novel member of the leucine-rich repeat protein family closely related to decorin and biglycan". The Journal of Biological ... The Journal of Biological Chemistry. 282 (44): 32193-9. PMID 17804408. doi:10.1074/jbc.M706262200. الوسيط ,التاريخ=. تم تجاهله ...
"The Journal of Biological Chemistry. 288 (7): 4878-90. doi:10.1074/jbc.M112.422410. PMC 3576092 . PMID 23275336.. ... Muñoz M, Rosso M, Coveñas R (Jun 2011). "The NK-1 receptor: a new target in cancer therapy". Current Drug Targets. 12 (6): 909- ... Unique among biological processes, SP release (and expression of its NK1 Receptor (through autocrine, paracrine, and endocrine- ... The Journal of Biological Chemistry. 279 (44): 45519-27. doi:10.1074/jbc.M408523200. PMID 15319441.. ...
In medicine, this era brought innovations such as open-heart surgery and later stem cell therapy along with new medications and ... including the possibility of the permanent alteration of our biological nature. These concerns are shared by other philosophers ...
Medical nutrition therapy is done by dietitians and is prescribed for diabetes, cardiovascular diseases, weight and eating ... Biomechanics is the study of the structure and function of biological systems by means of the methods of Mechanics. ... Biophysics is an interdisciplinary science that uses the methods of physics and physical chemistry to study biological systems. ... Histology is the study of the structures of biological tissues by light microscopy, electron microscopy and ...
Grissom RJ (1994). "Statistical analysis of ordinal categorical status after therapies". Journal of Consulting and Clinical ... Biological Reviews of the Cambridge Philosophical Society. 82 (4): 591-605. doi:10.1111/j.1469-185X.2007.00027.x. PMID 17944619 ...
Normally, the bone age is the same as the biological age but for some people, it is older. For many people with advanced bone ... Allen DB (July 2006). "Growth hormone therapy for short stature: is the benefit worth the burden?". Pediatrics. 118 (1): 343-8 ...
In the past 15 years, students have raised over $5 million to support treatment, research, and various therapies at the ... Museum of Biological Diversity, National Center for the Middle Market, Stone Laboratory on Gibraltar Island, OH, Center for ... Biological Sciences Building, CDME, Comprehensive Cancer Center, David Heart and Lung Research Institute, Electroscience ... ", "Biological Sciences Scholars", "International Affairs Scholars", "Business Scholars" and "Politics, Society and Law ...
Studies in History and Philosophy of Biological and Biomedical Sciences. 36 (1): 1-24. doi:10.1016/j.shpsc.2004.12.008.. ...
Biological activity[edit]. Androgens bind to and activate androgen receptors (ARs) to mediate most of their biological effects. ... For androgens as medications, see Anabolic steroid and Androgen replacement therapy.. Androgen. ... Biological function[edit]. Male prenatal development[edit]. Testes formation[edit]. During mammalian development, the gonads ... The Journal of Biological Chemistry. 280 (9): 7786-92. doi:10.1074/jbc.M413992200. PMID 15623502.. ...
"11.100.20: Biological evaluation of medical devices". Retrieved 10 April 2009.. *^ International Organization for ... The precipitant for change was a radiation therapy device (Therac-25) that overdosed patients because of software coding errors ... ISO 10993 - Biological Evaluation of Medical Devices. Cleanliness standardsEdit. Medical device cleanliness has come under ... Therapeutic: physical therapy machines like continuous passive range of motion (CPM) machines ...
Lithium naturally only occurs in traces in biological systems and has no known biological role, but does have effects on the ... Sartori, H. E. (1984). "Cesium therapy in cancer patients". Pharmacol Biochem Behav. 21 (Suppl 1): 11-13. doi:10.1016/0091-3057 ... Biological role and precautionsEdit. MetalsEdit. Pure alkali metals are dangerously reactive with air and water and must be ... Rubidium has no known biological role, but may help stimulate metabolism,[234][235][236] and, similarly to caesium,[234][237] ...
Experimental treatments include targeted therapy, gamma knife radiosurgery,[45] boron neutron capture therapy and gene therapy. ... These differences probably reflect some biological differences as well as differences in pathologic diagnosis and reporting.[51 ... Radiation therapyEdit. The goal of radiation therapy is to kill tumor cells while leaving normal brain tissue unharmed. In ... "Molecular Therapy. 12 (5): 842-51. doi:10.1016/j.ymthe.2005.03.017. PMID 16257382. Archived from the original on 12 September ...
A. Al Dayela and N. al-Zuhair (2006), "Single drug therapy in the treatment of male sexual/erectile dysfunction in Islamic ... mirip dengan pakaian dipakai oleh askar-askar moden untuk perlindungan terhadap senjata biological, kimia dan nukelar. Oleh ...
American Cancer Society Complete Guide to Complementary and Alternative Cancer Therapies (2nd ed.). American Cancer Society. ... The Journal of Biological Chemistry. 279 (26): 27008-16. doi:10.1074/jbc.M403588200. PMID 15090535.. ... quercetin undergoes rapid and extensive metabolism that makes the biological effects presumed from in vitro studies unlikely to ... "The metabolism and analysis of isoflavones and other dietary polyphenols in foods and biological systems". (review). Food & ...
Katsambas AD, Dessinioti C (2010). "Hormonal therapy for acne: why not as first line therapy? facts and controversies". Clin. ... from mediating their biological effects in the body. They act by blocking the androgen receptor (AR) and/or inhibiting or ... See also: Management of prostate cancer § Hormonal therapy, and Androgen deprivation therapy ... Mario Maggi (30 January 2012). Hormonal Therapy for Male Sexual Dysfunction. John Wiley & Sons. pp. 6-. ISBN 978-0-470-65760-7. ...
Intravenous interferon therapy has also been used.[citation needed] When Lassa fever infects pregnant women late in their third ... Werner, Dietrich, editor (2004). Biological Resources and Migration. Springer. p. 363. ISBN 978-3-540-21470-0.. CS1 maint: ... Effective therapy with ribavirin". The New England Journal of Medicine. 314 (1): 20-26. doi:10.1056/NEJM198601023140104. ISSN ...
Biological warfare. *Carcinogen. *Food safety. *Hazard symbol. *List of extremely hazardous substances ...
Research has identified health-behavioral and biological factors that are related to increased risk for CVD. These risk factors ... advantages of therapy with beta-receptor blockers. Clinical and Experimental Hypertension. Part A, Theory and Practice, 7(7), ...
Aerosolized-augmented A1AT therapy is under study. This involves inhaling purified human A1AT into the lungs and trapping the ... Coakley RJ, Taggart C, O'Neill S, McElvaney NG (January 2001). "Alpha1-antitrypsin deficiency: biological answers to clinical ... Recombinant alpha-1 antitrypsin is not yet available for use as a drug but is under investigation as a therapy for alpha-1 ... These products for intravenous augmentation A1AT therapy can cost up to $100,000 per year per patient. They are administered ...
Biological Reviews. 78 (2): 251-345. doi:10.1017/S1464793102006103. PMID 12803423.. *^ a b Sahney, S., Benton, M.J. & Falcon- ... "Theraputic potential of snake venom in cancer therapy: current perspective". Asian Pacific Journal of Tropical Medicine. 3 (2 ... "Proceedings of the Royal Society B: Biological Sciences. 274 (1610): 635-640. doi:10.1098/rspb.2006.3763. PMC 2197205. PMID ... Biological and Biomedical Sciences. 39 (3): 298-313. doi:10.1016/j.shpsc.2008.06.004. PMID 18761282.. ...
"ChEBI: Bitolterol". Chemical Entities of Biological Interest. Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK. ... Jan 1984). "Concomitant bitolterol mesylate aerosol and theophylline for asthma therapy, with 24 hr electrocardiographic ... The Journal of Human Pharmacology and Drug Therapy. 5 (3): 127-137. doi:10.1002/j.1875-9114.1985.tb03410.x. PMID 3895171. " ...
Endicott, S. L.; Hageman, E. (1998). The United States and Biological Warfare: Secrets from the Early Cold War and Korea. ... it had been previously discounted as a possible therapy.[103] Infection was reduced in mosquitoes with the wMel strain of ... Yellow fever has been researched by several countries as a potential biological weapon.[105] ...
Expert Opinion on Biological Therapy is a monthly peer-reviewed medical journal covering research on all aspects of biological ... "Expert Opinion on Biological Therapy". 2017 Journal Citation Reports. Web of Science (Science ed.). Thomson Reuters. 2018. ... therapy, including gene therapy and gene transfer technologies, therapeutic peptides and proteins, vaccines and antibodies, and ... cell- and tissue-based therapies. The journal is published by Taylor & Francis and the editor-in-chief is Michael Morse (Duke ...
TNF inhibiting biological therapies were initially used in IBD patients who werent responding to conventional therapy. They ... which often does not include traditional biological substances like vaccines. Today, biological therapy most commonly refers to ... Biological therapy has found a niche in the management of cancer, autoimmune diseases, and diseases of unknown cause that ... The advancements in biological therapy greatly changed how IBD is treated. Patients with Crohns disease and ulcerative colitis ...
Targeted Radionuclide Tumor Therapy: Biological Aspects. Torgny Stigbrand,Jorgen Carlsson,Gregory P. Adams. No preview ... Targeted Radionuclide Tumor Therapy: Biological Aspects. Torgny Stigbrand,Jorgen Carlsson,Gregory P. Adams. No preview ... The title of this book "Targeted Radionuclide Tumour Therapy - Biological Aspects" was selected to reinforce the concept that a ... activation Affibody molecule affinity antigen apoptosis apoptotic Auger electrons binding biodistribution Biol biological ...
Biological therapies for cancer. National Cancer Institute. http://www.cancer.gov/cancertopics/factsheet/Therapy/biological. ...
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. H Aguilar1, X Solé2,3, N Bonifaci2,3, J ... Ghayad et al., 2009). Notably, ERBB2 amplification was associated with resistance to endocrine therapies (. Ellis et al., 2006 ... Endocrine therapies are the most effective systemic treatment of estrogen receptor α (ERα)-positive breast cancer, and over two ... Winer et al., 2002). Two major strategies mediate the efficacy of these therapies. Drugs directed at ERα, mainly tamoxifen and ...
Biological therapy may be used to treat chronic myelogenous leukemia in the chronic or accelerated phase. Learn about ... Biological therapy drug used for CML. Interferon alfa (Intron A, Wellferon) is the biological therapy occasionally used to ... Biological therapy is also called biotherapy or biological response modifiers (BRMs).. In most cases, targeted therapies are ... Biological therapy for chronic myelogenous leukemia. Biological therapy is sometimes used to treat chronic myelogenous leukemia ...
... biological response modifiers and the family of cell adhesion-promoting molecules. ... Biological Treatments in Behçets Disease: Beyond Anti-TNF Therapy. Francesco Caso,1,2 Luisa Costa,3 Donato Rigante,4 Orso ... We found 44 cases of BD patients in therapy with biological agents other than anti-TNF-α agents. In particular, we found eight ... corticosteroid therapy is recommended for dural sinus thrombosis, while a combination therapy of corticosteroids with ...
Learn how and when biological therapy is used and side effects of biological therapy. ... Biological therapy is used treat certain types of non-Hodgkin lymphoma. ... Biological therapy is also called biotherapy or biological response modifiers (BRMs).. You may have biological therapy to:* ... Biological therapy for non-Hodgkin lymphoma. Biological therapy is sometimes used to treat non-Hodgkin lymphoma (NHL). It uses ...
Is it safe to use biologic therapies for psoriasis in women of child-bearing age? This systemic review found that the safety of ... Exposure to Biological Therapies During Conception and Pregnancy. A Systematic Review. E. Pottinger; R.T. Woolf; L.S. Exton; A. ... The aim of the review was to investigate outcomes in women exposed to biological therapies relevant to the treatment of ... has received departmental funding for research from pharmaceutical companies involved in manufacturing biological therapies ...
Is it safe to use biologic therapies for psoriasis in women of child-bearing age? This systemic review found that the safety of ... Exposure to Biological Therapies During Conception and Pregnancy. A Systematic Review. E. Pottinger; R.T. Woolf; L.S. Exton; A. ... Background Biological therapies are effective treatments for psoriasis and are often prescribed to women of child-bearing age. ... All of the biological therapies currently licensed for psoriasis are derivatives of human immunoglobulin G (IgG) and are ...
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.. Miller WR1, Dixon JM, Cameron DA, Anderson TJ. ... there was a decrease with therapy in immunohistochemical staining for Ki67 in all tumours. Staining for progesterone receptor ( ...
Biological therapy downregulates the heterodimer S100A8/A9 (calprotectin) expression in psoriatic patients. ... the expression of the heterocomplex S100A8/A9 in lesional skin from psoriatic patients undergoing biological therapy with ... Balato A, Schiattarella M, Di Caprio R, Lembo S, Mattii M, Balato N, Ayala F. Effects of adalimumab therapy in adult subjects ... Furthermore, we have shown that the biological treatment induced a drastic reduction of S100A8/A9 expression in skin biopsies ...
The light ions have a unique role in the development of modern radiation therapy where biological optimized radiation quality ... and intensity-modulated radiation therapy are increasingly coming into... ... The light ions have a unique role in the development of modern radiation therapy where biological optimized radiation quality ... Brahme A. (2011) Physical, Biological and Clinical Background for the Development of Light Ion Therapy. In: Levitt S., Purdy J ...
Targeted (biological) therapies information for you Related. Order booklets or audio CDs about targeted (biological) therapies ... biological or hormonal therapies, transplants, and clinical trials.. Latest posts in Cancer treatments. Jenny62 replied to jane ...
CRISPR-Responsive Materials Deliver Therapy on Biological Cues. August 29th, 2019 Medgadget Editors Genetics, Materials, ... giving smart biological functionality to whatever material it is in. ... deliver therapies, and do things that are currently impossible. ... Nanoparticles for Large Gene Therapy to Cure Common Eye ...
... By Jonathan Lotempio, Jr.. Scientific Program Analyst, NHGRI. Ludwig ... While gene therapy with AAV2/1-Cba-Tmc1 would likely not have helped Beethoven, since scholars can be nearly certain that he ... Gene therapy, however, may answer that technologic need. Adeno-associated viruses (AAV) have long been a promising vector for ... Tmc gene therapy restores auditory function in deaf mice. Sci Transl Med, 7(295):295ra108. 2015. [PubMed] ...
Download all the latest market reports you need on the Biological Therapy Industry in Europe. Click here to instantly access ... Global Stem Cell Therapy Market Analysis & Trends - Ind ... $ 4200 November 2017 The Global Stem Cell Therapy Market is poised ... Biological Therapy Industry in Europe Market Research & Statistics. Biological Therapy Industry in Europe Market Research & ...
Download all the latest market reports you need on the Biological Therapy Industry in Thailand. Click here to instantly access ... Biological Therapy Industry in Thailand Market Research & Statistics. Biological Therapy Industry in Thailand Market Research ...
Biological proteins have unlimited potential for use as pharmaceutical products due to their various biological activities, ... allow for the development of novel innovative protein-based products that draw on the quality of their innate biological ... review attempts to provide an overview of the development of protein-based products that take advantage of their biological ... Potential Use of Biological Proteins for Liver Failure Therapy. Kazuaki Taguchi 1. ...
Professor Working with Cincinnati Startup to Develop Biological Therapy. Cedarville News Professor Working with Cincinnati ... Startup to Develop Biological Therapy by Nathan Pilling, Public Relations Writer. Thursday, May 30, 2013. There is a growing ... to work on a novel biological approach to stabilize blood vessels. Photo credit: Scott L. Huck/Cedarville University ... to work on a novel biological approach to stabilize blood vessels. ...
... Steven M ... Other promising approaches include antiretroviral therapy with interleukin (IL) -2, and IFN-α wilh IL-2. The clinical research ... Therefore, approaches to attacking HIV via combination therapies have recently been under investigation. In particular, since ... pertaining to these combinations of antiretrovirals and biological response modifiers is reviewed. ...
Biological: aldesleukin Biological: cytokine therapy Biological: sargramostim Drug: carboplatin Drug: cyclophosphamide Drug: ... Biological Therapy in Treating Women With Metastatic Breast Cancer. The recruitment status of this study is unknown. The ... RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining ... PRIOR CONCURRENT THERAPY: See Disease Characteristics No concurrent hormonal therapy for breast cancer ...
"Biological Therapy" by people in Harvard Catalyst Profiles by year, and whether "Biological Therapy" was a major or minor topic ... "Biological Therapy" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Biological Therapy" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Biological Therapy". ...
Thank you for your interest in either the Physical Therapy or Occupational Therapy Internship (Bio 498). Dr. Jim MacKenzie is ...
People searching for Bachelors Degree in Biological Therapy found the following resources, articles, links, and information ... Bachelors Degree in Biological Therapy. Schools dont offer a biological therapy bachelors degree. For students who want to ... Diploma in Body Therapy: Program Overview Body therapy is generally used to describe massage therapy, body movement therapies, ... Students interested in biological therapy can earn a bachelors degree in immunology, biochemistry, or biology to learn the ...
Biological: aldesleukin Biological: lymphokine-activated killer cells Biological: therapeutic tumor infiltrating lymphocytes ... Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining biological ... Prostaglandin Inhibition Therapy plus Biological Response Modifier Therapy. Indomethacin; plus CTX; IL-2-activated TIL; IL-2. ... Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma. The safety and scientific validity of this ...
Medical Therapy Can Improve the Biological Properties of the Chronically Failing Heart. A New Era in the Treatment of Heart ... Evidence That Medical Therapy Can Improve the Inherent Biological Function of the Failing Heart. Because the natural history of ... Evidence That Medical Therapy Can Improve the Inherent Biological Function of the Failing Heart ... Evidence That Medical Therapy Can Improve the Inherent Biological Function of the Failing Heart ...
... psychiatry residents and other mental health professionals an introduction to the combined use of psychological and biological ... Home , Books , Integrating Psychological and Biological Therapies View PDF. Integrating Psychological and Biological Therapies ... Integrating Psychological and Biological Therapies is included in the following Collections:. *Lippincott Williams & Wilkins ... Journal of Physical Therapy Education The premier forum for disseminating scholarly works in physical therapy educational ...
Combined with acupuncture therapy, placental extract extends its therapeutic limit to pain control. Recently, we have reported ... Placenta Therapy: Its Biological Role of Anti-Inflammation and Regeneration. By Kyeong Mee Park, Dong Pill Cho and Tae Hwan Cho ... Kyeong Mee Park, Dong Pill Cho and Tae Hwan Cho (November 5th 2018). Placenta Therapy: Its Biological Role of Anti-Inflammation ... Kyeong Mee Park, Dong Pill Cho and Tae Hwan Cho (November 5th 2018). Placenta Therapy: Its Biological Role of Anti-Inflammation ...
What are the different types of biological therapies?. Side effects. What is biological therapy?. Biological therapy (also ... Vaccine therapy - is still an experimental biological therapy. The benefit of vaccine therapy has not yet been proven. With ... Biological therapy. What is biological therapy?. How does the immune system fight cancer?. ... What are the different types of biological therapies?. There are many different types of biological therapies used in cancer ...
  • Abstract CN12-02: Dietary HDAC inhibitors: Prevention or therapy? (aacrjournals.org)
  • Cold viruses generally get a bad rap----which they've certainly earned----but new findings by a team of scientists at the Salk Institute for Biological Studies suggest that these viruses might also be a valuable ally in the fight against cancer. (biospace.com)
  • Although the use of antibodies to treat diseases can be dated back to the 1800s, biologic therapy as we know it today is a relatively new concept for the treatment of inflammatory bowel disease. (wikipedia.org)
  • Even so, biologic therapy still has its faults such as high cost and risk of side effects. (wikipedia.org)
  • Targeted therapy, also called biologic therapy, uses the body's immune system or hormonal system to fight breast cancer cells. (webmd.com)
  • Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. (harvard.edu)
  • Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease. (harvard.edu)
  • Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. (harvard.edu)
  • Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry. (harvard.edu)
  • Side effects of biologic therapy were infections such as urinary tract infections and soft tissue abscess. (dovepress.com)
  • All these factors can inhibit the growth of global cancer biologic therapy market trend. (fractovia.org)
  • Japan cancer biologic therapy market share contributed for more than 40.1% of overall revenue share of APAC for 2015 owing to its rising old age population. (fractovia.org)
  • this will be compared with physical activity levels at baseline and the change in these level pre and post treatment with biologic therapy. (bioportfolio.com)
  • Biological therapy is also called biotherapy or biological response modifiers (BRMs). (cancer.ca)
  • The clinical research pertaining to these combinations of antiretrovirals and biological response modifiers is reviewed. (hindawi.com)
  • Biological response modifiers - change the way the body's defenses interact with cancer cells. (vcu.edu)
  • Biological therapy for cancer often causes fewer toxic side effects than do other cancer treatments. (mayoclinic.org)
  • There are several ways biological therapy treatments can achieve this goal. (mayoclinic.org)
  • Background Biological therapies are effective treatments for psoriasis and are often prescribed to women of child-bearing age. (medscape.com)
  • Biological therapies are effective treatments for psoriasis that specifically block proinflammatory cytokine pathways central to disease immunopathogenesis. (medscape.com)
  • They can also be combined with other treatments, such as chemotherapy and radiation therapy. (vidanthealth.com)
  • Hormone therapy is used to treat breast cancer that is hormone sensitive ( where the presence of estrogen and/or progesterone receptors are found) These hormone treatments work by lowering the level of estrogen in the body or by blocking the action of estrogen on breast cancer cells. (nygh.on.ca)
  • Main outcome measures included change in the ongoing treatments with corticosteroids, IMT and biological agents, use of alternate therapies and rates of uveitis relapse. (bmj.com)
  • The FDA has approved multiple targeted drug cancer therapies, and many more are being studied in clinical trials either alone or in combination with other treatments. (sinobiological.com)
  • Two major strategies mediate the efficacy of these therapies. (nature.com)
  • The aim of our study was to evaluate the efficacy and safety of biological therapy for AOSD resistant to traditional therapy. (dovepress.com)
  • The efficacy of biological therapy and overall tolerance of biological therapy for refractory AOSD were good. (dovepress.com)
  • Discussion ETN has proved its efficacy in JIA (regardless of the type of onset), as it has been reported in multiple efficacy and safety studies, including long term studies of up to eight years of continuous therapy. (bmj.com)
  • While replacement therapy remained unrealistic, the clinical efficacy of this therapeutic option could be potentially enhanced if we could better decipher the mechanisms underlying some of the beneficial effects of transplanted cells, and work toward augmenting or combining these in a strategic manner. (degruyter.com)
  • Many types of biological therapy are available only in clinical trials. (mayoclinic.org)
  • Data generated from both clinical trials and model systems indicate that both types of therapy may prevent the progression of pump dysfunction that characterizes the natural history of heart failure and, unexpectedly and remarkably, that β-blockade may substantially improve pump function in the long term. (ahajournals.org)
  • The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products. (bccresearch.com)
  • Noncytotoxic maneuvers that short circuit damage resistance loops may thus represent an indirect form of gene therapy meriting incorporation into hepatocellular carcinoma clinical trials. (aacrjournals.org)
  • Allowing Innovative Stem Cell-Based Therapies Outside of Clinical Trials: Ethical and Policy Challenges. (philpapers.org)
  • Targeted therapy is a newer type of cancer treatment that uses drugs or other substances to more precisely identify and attack cancer cells, usually while doing little damage to normal cells.It has been validated to be a curative treatment for cancer, with many clinical trials and approved by FDA. (sinobiological.com)
  • Different types of biological therapies work in different ways. (cancer.ca)
  • Combining different types of biological therapies may kill more tumor cells. (clinicaltrials.gov)
  • What are the different types of biological therapies? (vcu.edu)
  • Many types of biological therapy are available only in clinical trails Biological therapy for cancer treatment is a very active area of cancer treatment. (findatopdoc.com)
  • https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/bio-therapies-fact-sheet. (mayoclinic.org)
  • Biological therapy, otherwise known as immunotherapy, is an innovative procedure used to treat cancer through immune system techniques. (study.com)
  • Biological therapy (also called immunotherapy, biological response modifier therapy or biotherapy) uses the body's immune system to fight cancer. (vcu.edu)
  • Biological therapy is also called immunotherapy, biological response modifier therapy, or biotherapy. (vidanthealth.com)
  • Radio-immunotherapy therapy, photodynamic therapy, and thermal therapies can also be classified under this heading. (survivingmesothelioma.com)
  • RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. (clinicaltrials.gov)
  • Nonspecific immunomodulating agents - biological therapy drugs that stimulate the immune system, causing it to produce more cytokines and antibodies to help fight cancer and infections in the body. (vcu.edu)
  • Nonspecific immunomodulating agents are biological therapy drugs that stimulate the immune system in a general way. (vidanthealth.com)
  • RATIONALE: Biological therapies, such as agatolimod, may stimulate the immune system in different ways and stop tumor cells from growing. (bioportfolio.com)
  • Biological therapy for cancer is a type of treatment that uses the body's immune system to kill cancer cells. (mayoclinic.org)
  • The aim of the review was to investigate outcomes in women exposed to biological therapies relevant to the treatment of psoriasis at conception and/or during pregnancy to assess the impact of such exposure. (medscape.com)
  • Population-based cohort studies or clinical trial data were eligible for review which evaluated pregnancy outcomes in women exposed during conception or pregnancy to biological therapies relevant to the treatment of psoriasis. (medscape.com)
  • Psoriasis often first develops in young adults, of which a significant number may require treatment with a biological agent. (medscape.com)
  • All of the biological therapies currently licensed for psoriasis are derivatives of human immunoglobulin G (IgG) and are actively transported across the placenta via neonatal Fc receptors. (medscape.com)
  • Therefore, additional therapies for a subset of refractory patients with BD are inevitably needed. (hindawi.com)
  • The advent of biological tumor necrosis factor-α (TNF-α) inhibitors has led to substantial improvement in management of severe and active PsA refractory to conventional DMARD. (jrheum.org)
  • CD19-specific chimeric antigen receptor (CAR) T-cell therapy is highly effective against relapsed or refractory acute lymphoblastic leukemia (ALL), but is hindered by neurotoxicity. (aacrjournals.org)
  • The investigation of molecular biological mechanisms and therapy of refractory renal edema. (nii.ac.jp)
  • This study was designed to investigate the mechanisms and therapy of refractory renal edema. (nii.ac.jp)
  • However, most breast tumors initially responsive to these therapies develop resistance through molecular mechanisms that are not yet fully understood. (nature.com)
  • However, although endocrine therapies are initially effective, resistance occurs both in the form of tumor relapse after excision during adjuvant treatment and as a near-universal event when tumors cannot be excised. (nature.com)
  • DEDIĆ PLAVETIĆ NDP, BARIĆ MB, BRADIĆ LB, KULIĆ A, PLEŠTINA S. Hypoxia in solid tumors: biological responses to hypoxia and implications on therapy and prognosis. (srce.hr)
  • N.D.P. DEDIĆ PLAVETIĆ, M.B. BARIĆ, L.B. BRADIĆ, A. KULIĆ i S. PLEŠTINA, "Hypoxia in solid tumors: biological responses to hypoxia and implications on therapy and prognosis", Periodicum biologorum , vol.116, br. (srce.hr)
  • Methods to augment the biological action of radiation therapy in prostate and other tumors without additional toxicity to surrounding normal tissues would be useful for improving the therapeutic ratio. (nanotech-now.com)
  • This book serves as a comprehensive guide to the rapidly evolving field of molecular neuropathology of nervous system tumors, as well as the underlying biology and emerging molecular targeted therapies. (ebookee.org)
  • Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. (wikipedia.org)
  • Given this, a variety of biological therapies (such as TNF inhibitors and interleukin antagonists) have been developed for the treatment of these diseases. (wikipedia.org)
  • The previous treatment options had many shortcomings, and the introduction of biological therapy changed the way physicians treat Crohn's disease and ulcerative colitis. (wikipedia.org)
  • Today, biological therapy most commonly refers to the use of proteins, such as monoclonal antibodies, to regulate the immune system in the treatment of disease. (wikipedia.org)
  • Prior to the development of biological therapy as a modality to treat IBD, other medications that modulate the immune system-including 5-aminosalicylates, steroids, azathioprine, and other immunosuppressants-were primarily used in treatment. (wikipedia.org)
  • Biological therapy for cancer is used in the treatment of many types of cancer to prevent or slow tumor growth and to prevent the spread of cancer. (mayoclinic.org)
  • Endocrine therapies targeting the proliferative effect of 17β-estradiol through estrogen receptor α (ER α ) are the most effective systemic treatment of ER α -positive breast cancer. (nature.com)
  • In most cases, targeted therapies are now the main treatment for CML. (cancer.ca)
  • However, although biological treatment with anti-TNF- α agents has been largely demonstrated to be effective in BD, not all patients are definite responders, and this beneficial response might drop off over time. (hindawi.com)
  • Furthermore, we have shown that the biological treatment induced a drastic reduction of S100A8/A9 expression in skin biopsies from treated patients, correlating with PASI reduction. (springer.com)
  • Brahme A (2009) Potential developments of light ion therapy: the ultimate conformal treatment modality. (springer.com)
  • Order booklets or audio CDs about targeted (biological) therapies, how they work, having treatment and how it might affect you. (macmillan.org.uk)
  • This review attempts to provide an overview of the development of protein-based products that take advantage of their biological activity for medication, and discusses possibilities for the therapeutic potential of protein-based products produced through different approaches to specifically target the liver (or hepatic cells: hepatocytes, hepatic stellate cells, liver sinusoidal endothelial cells, and Kupffer cells) in the treatment of hepatic diseases. (mdpi.com)
  • 16 17 18 19 20 These two types of therapies, ACE inhibitors and β-adrenergic-blocking agents, have changed our thinking about the potential of medical treatment of heart failure. (ahajournals.org)
  • Chapters present treatment strategies for those conditions for which research and clinical experience have clearly demonstrated the benefits of combination therapy-major depression, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, sleep disorders, schizophrenia, bipolar disorder, borderline personality, and generalized anxiety disorder. (silverplatter.com)
  • Advances in imaging and biological targeting have led to the development of stereotactic body radiation therapy (SBRT) as an alternative treatment of extracranial oligometastases. (biomedsearch.com)
  • Boron neutron capture therapy (BNCT) has been investigated as a potential treatment for glioblastoma multiforme (GBM), head and neck cancers, melanoma, and other tumor sites for many decades. (mdpi.com)
  • Increase in proportion of different kinds of cancers and rising acceptance of biological treatment is predicted to drive global cancer biological therapy industry trends. (fractovia.org)
  • High treatment cost of cancer therapy is mainly owing to high price of medicines. (fractovia.org)
  • Biological therapies for treatment of other diseases will not be addressed in this report. (bccresearch.com)
  • Are there any special instructions I should follow before, during, and after each biological treatment? (nygh.on.ca)
  • Will there be any interactions between the complementary therapy and your conventional cancer treatment? (nygh.on.ca)
  • These findings suggest that reovirus therapy may provide a promising novel treatment for prostate cancer and also imply a possible role for viral immune targeting of tumor. (aacrjournals.org)
  • At diagnosis, mean age was 4.94 ± 2.9, and at the beginning of biological treatment of 8.77 ± 2.63. (bmj.com)
  • Actually all the children are in remission, two of them (patients 1 and 4) without biological treatment or classic DMARDs (since 5 and 2 years respectively). (bmj.com)
  • The Photodynamic therapy (PDT) is a treatment that kills cancer cells by using special drugs, called photosensitizing agents, along with light. (placidway.com)
  • Prostate cancer treatment can be applied in a number of combinations along with complementary therapies. (placidway.com)
  • Biological therapy means treatment with agents that are natural biologic products (such as antibodies from other species, etc. (healthtap.com)
  • To analyze the details of treatment, treatment outcomes and associated-systemic diseases in the scleritis patients who have received immunosuppressant and biological agents at Ocular Inflammation Service of the Nippon Medical School Hospital (NMSH), Ophthalmology. (arvojournals.org)
  • ALL of 24 patients succeeded in steroid-sparing after treatment with immunosuppressant or biological agents, and 10 out of 24 patients were eventually led to steroid-free. (arvojournals.org)
  • Immunosupressant and biological agents are effective treatment for scleritis. (arvojournals.org)
  • The subjects who are eligible to enter in the study will receive his/her normal treatment prescribed and be at the referral phase for biological treatment. (bioportfolio.com)
  • A disease activity score (aggregate score of RA symptoms - DAS) for the RA population will be calculated by a nurse specialist at the time of referral for the biological agent and again at 12 weeks post treatment, these parameters will not be repeated by the research team but the DAS score will be collected used in the final analysis. (bioportfolio.com)
  • This screening / baseline visit will occur before, but as near as possible to the 1st treatment day of the prescribed biological agent. (bioportfolio.com)
  • Some patients with these cancers can be treated with targeted genetic therapies, and some benefit from immunotherapies-but the vast majority of NSCLC patients have no treatment options except for chemotherapy. (salk.edu)
  • Future research may further identify when and/or which patients are most likely to discontinue biological treatment successfully. (nih.gov)
  • To evaluate the performance of biological drugs in psoriatic arthritis (PsA) in a routine care setting, using the Finnish national register of biological treatment (ROB-FIN). (jrheum.org)
  • However, evidence of the clinical benefit of DMARD therapy in treatment of PsA is largely inconclusive 3 , 4 . (jrheum.org)
  • To evaluate the effectiveness and adverse events (AE) of biological therapies in the treatment of inflammatory arthritides, the Finnish Society for Rheumatology has set up a national register of biological treatment (ROB-FIN) 9 , 10 , 11 , 12 , 13 , maintained with approval from the Internal Medicine Ethics Committee of the Hospital District of Helsinki and Uusimaa. (jrheum.org)
  • Patient selection for biological therapy of PsA with peripheral arthritis has, presumably, been based on the national evidence-based treatment recommendations (the so-called Current Care guidelines) for rheumatoid arthritis (RA) 18 , but with modification based on the clinical judgment of a specialist to accomodate individual patient needs. (jrheum.org)
  • The Hyperthermia Centre in Hannover is among the leading biological cancer treatment clinics in Germany. (hyperthermia-centre-hannover.com)
  • The aim of this prospective, randomized, clinical trial was to compare outcomes of treatment in persons with chronic diabetic foot ulcers (DFUs) randomly assigned to transdermal continuous oxygen therapy (TCOT) for 4 weeks as an adjunct to standard care (debridement, offloading, and moisture). (o-wm.com)
  • High-energy Extracorporeal Shock-Wave Therapy (ESWT) for the treatment of chronic plantar fasciitis. (semanticscholar.org)
  • The type of targeted therapy your doctor might recommend depends on the type of breast cancer you have. (webmd.com)
  • Some postmenopausal women with certain types of advanced breast cancer may get a prescription for palbociclib (Ibrance) or ribociclib (Kisqali) along with hormone therapy. (webmd.com)
  • This study provides mechanistic insight into acquired resistance to endocrine therapies of breast cancer and highlights a potential therapeutic strategy. (nature.com)
  • Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy. (harvard.edu)
  • Expert Opinion on Biological Therapy is a monthly peer-reviewed medical journal covering research on all aspects of biological therapy, including gene therapy and gene transfer technologies, therapeutic peptides and proteins, vaccines and antibodies, and cell- and tissue-based therapies. (wikipedia.org)
  • July's Genome Advance of the Month highlights a study in the journal Science Translational Medicine that demonstrated gene therapy as an effective way to improve hearing in patients with two genes linked to genetic prelingual deafness, or hearing loss that occurs before a child learns to speak. (genome.gov)
  • The study's authors, Charles Askew, Ph.D., Jeffery R. Holt, Ph.D. and colleagues at École Polytechnique Fédérale de Lausanne in Switzerland, examined the use of gene therapy to cure hereditary deafness in mice with two types of Tmc1 mutations. (genome.gov)
  • Gene therapy, however, may answer that technologic need. (genome.gov)
  • Adeno-associated viruses (AAV) have long been a promising vector for human gene therapy due to their apparent inability to cause disease or integrate their viral genome into the human host genome. (genome.gov)
  • The hearing abilities of mice treated with this gene therapy were tested by analyzing the brain function and startle response to unexpected auditory stimuli (sounds). (genome.gov)
  • While gene therapy with AAV2/1- Cba - Tmc1 would likely not have helped Beethoven, since scholars can be nearly certain that he was not a carrier of a mutant TMC1 gene, this promising genomic discovery may eventually enable those who do have deafness caused by a TMC1 mutation to regain their ability to hear. (genome.gov)
  • What are 3 benefits of gene therapy? (healthtap.com)
  • Here is some comprehensive information about gene therapy . (healthtap.com)
  • This suggests that STAT3 is a promising molecular target for HCC gene therapy. (checkorphan.org)
  • The goal of biological therapy for cancer is to induce your immune system to recognize and kill cancer cells. (mayoclinic.org)
  • Biological therapy can also target the cancer cells, turning on or off cell signals that help them elude the immune system cells. (mayoclinic.org)
  • Biological therapies are designed to boost the immune system, either directly or indirectly. (vidanthealth.com)
  • Biological therapy targets work with your immune system to target cancer cells, unlike traditional chemotherapy, which kills dividing cells (whether normal or cancerous). (nygh.on.ca)
  • In general, biological therapies work in one of two ways: Inducing the immune system to attack cells. (findatopdoc.com)
  • The aim of this study was to investigate, by immunohistochemical analysis, the expression of the heterocomplex S100A8/A9 in lesional skin from psoriatic patients undergoing biological therapy with adalimumab, etanercept or ustekinumab. (springer.com)
  • They also are produced in the laboratory and given to cancer patients in biological therapy. (vcu.edu)
  • Thirty two of 271 patients given anti-TNF-α therapies (11.81%), 116 patients receiving IL-1 inhibitors (65.54%), 124 patients receiving tocilizumab (76.07%), and 13 patients given other biological therapies (36.11%) achieved remission. (dovepress.com)
  • Although clinical data shows much beneficial effects of biological therapies in terms of reduction of exacerbation rates, improvement of lung functions, asthma control and patients' quality of life, little is known on the effects of these monoclonal antibodies on AR-a key clinical trait of long-term asthma management. (frontiersin.org)
  • The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease. (centerwatch.com)
  • Patients who required immunosapressant and biological agents were 24 patients (10%) out of 227 patients with scleritis. (arvojournals.org)
  • Extraglandular involvement requires organ-specific therapy generally based upon some combination of glucocorticoids and immunosuppressive agents, similar to that applied in patients with systemic lupus erythematosus (SLE) [1]. (springer.com)
  • Readers should verify all information and data before treating patients or using any therapies described in these materials. (clinicaloptions.com)
  • We used the electroretinogram (ERG) to assess seasonal change in retinal function in patients with SAD and healthy participants, as well as in patients following 4 weeks of light therapy. (prohealth.com)
  • ERG assessments were obtained in 22 SAD patients (2 men, 20 women, mean age 31 +/- 9 years) in the fall/winter season before and after 2 and 4 weeks of light therapy and in summertime. (prohealth.com)
  • A significantly lower cone ERG maximal amplitude and lower rod sensitivity was found in SAD patients before light therapy compared with healthy participants. (prohealth.com)
  • After achieving low disease activity or remission, biological therapy might be stopped in rheumatoid arthritis patients, but information on whether and how this should be done is scarce. (nih.gov)
  • In most studies, patients were required to have low disease activity or be in clinical remission for at least 6 months before biological therapy was discontinued. (nih.gov)
  • In conclusion, in the absence of a guideline for stopping biologicals in RA, we present a preliminary proposal that biological therapy can be stopped in many RA-patients after achieving low disease activity or remission for at least 6 months. (nih.gov)
  • Patients with PsA who started therapy with infliximab or etanercept between June 2000 and February 2006 (n = 127) were followed for up to 24 months. (jrheum.org)
  • Anti-tumor necrosis factor-α therapy, often combined with conventional disease-modifying antirheumatic drugs, appeared to have limited toxicity and persistent effectiveness for up to 2 years in a cohort of Finnish patients with severe peripheral PsA. (jrheum.org)
  • The aim of this study was to investigate the microRNA expression pattern in neutrophils from rheumatoid arthritis patients and its contribution to their pathogenic profile and to analyze the effect of specific autoantibodies or inflammatory components in the regulation of microRNAs in rheumatoid arthritis neutrophils and its modulation by biological therapies. (haematologica.org)
  • Purpose To evaluate the change in the ongoing immunomodulatory (IMT) and biological therapies among patients with non-infectious uveitis (NIU), and determine the number of uveitis relapses during the COVID-19 pandemic. (bmj.com)
  • See all available therapies at the Hyperthermia Centre Hannover, Germany explained in Dr Peter Wolf's book for patients and relatives. (hyperthermia-centre-hannover.com)
  • Screening for latent tuberculosis infection in patients who are candidate for biological therapies in Spain? (archbronconeumol.org)
  • Effects of Low-Level Laser Therapy in Orthodontic Patients on Immediate Inflammatory Response After Mini-Implants Insertion: A Preliminary Report. (semanticscholar.org)
  • Plant derivatives and hormone therapy corticosteroids. (bccresearch.com)
  • Hormone therapy is a pill that is taken daily. (nygh.on.ca)
  • Side effects may arise from hormone therapy. (nygh.on.ca)
  • What are the benefits and risks of hormone therapy? (nygh.on.ca)
  • What type of hormone therapy am I getting? (nygh.on.ca)
  • You will need to have blood drawn in the outpatient lab on the 4th floor , the day before you begin hormone therapy. (nygh.on.ca)
  • Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. (nih.gov)
  • Biological therapies can be defined as targeted therapies used to attack a particular protein, enzyme or other cellular component or an approach using inhibitors (i.e. anti-angiogenesis), monoclonal antibodies or other substances. (survivingmesothelioma.com)
  • The aim of this review is to summarize all current experiences and the most recent evidence regarding these novel approaches with biological drugs other than TNF- α blockers in BD, providing a valuable addition to the actually available therapeutic armamentarium. (hindawi.com)
  • Combined with acupuncture therapy, placental extract extends its therapeutic limit to pain control. (intechopen.com)
  • The journal provides assistance in the development of knowledge about biological markers, fast operative publication of scientific advances to the development of new guided-therapeutic strategies based on diagnostic, and prognostic biological markers to help scientists cooperation in their different modern researches. (m-hikari.com)
  • These implantable devices are an essential technical component of radiation delivery during Image Guided Radiation Therapy (IGRT), but are inert and provide no direct therapeutic function. (nanotech-now.com)
  • Background Biological therapies have dramatically changed the prognosis for children with juvenile idiopathic arthritis (JIA). (bmj.com)
  • Background- Biological pacing performed solely via HCN2 gene transfer in vivo results in relatively slow idioventricular rates and only moderate autonomic responsiveness. (ahajournals.org)
  • Accurate dosimetry and determination of the biological effectiveness of boron neutron capture therapy (BNCT) is challenging because of the mix of different types and energies of radiation at the cellular and subcellular levels. (mdpi.com)
  • We envisaged N-benzyl derivatives of the polyamines as vectors of (10)B and (18)F for boron neutron capture therapy (BNCT) and tumor imaging by positron emission tomography (PET), respectively. (nih.gov)
  • Na[COSAN], which displays low toxicity and high uptake by relevant cancer cells accumulating boron within the nucleus, could act as a suitable compound for further developments as boron neutron capture therapy (BNCT) agents. (icmab.es)
  • The title of this book "Targeted Radionuclide Tumour Therapy - Biological Aspects" was selected to reinforce the concept that a major focus of this volume was devoted to understanding the biological effects of targeting and radiation. (google.com)
  • The light ions have a unique role in the development of modern radiation therapy where biological optimized radiation quality and intensity-modulated radiation therapy are increasingly coming into clinical interest, not least through a systems biology approach to therapy optimization. (springer.com)
  • The traditional dose distributional qualities of light ions like penumbra and depth dose are ideally suited for high-quality radiation therapy, and their radiation biological properties are even more important for eradicating large complex generally radiation resistant and/or hypoxic tumor volumes with minimal damage to surrounding normal tissues. (springer.com)
  • Brahme A (1984) Dosimetric precision requirements in radiation therapy. (springer.com)
  • Brahme A (1988) Optimization of stationary and moving beam radiation therapy techniques. (springer.com)
  • Brahme A (2003) Biologically optimized 3-dimensional in vivo predictive assay based radiation therapy using positron emission tomography-computerized tomography imaging. (springer.com)
  • Brahme A (2004) Recent advances in light ion radiation therapy. (springer.com)
  • Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review. (biomedsearch.com)
  • Radiation therapy. (bccresearch.com)
  • In order to achieve high spatial accuracy, modern radiation therapy practice routinely utilizes implantation of fiducials (external beam therapy) or radioactive source spacers (brachytherapy) into the tumor. (nanotech-now.com)
  • Comparison with the extent of kidney injury determined by histological changes five to eight months after administration of the same 177Lu-folate activities suggested that the quantitative assessment of double-strand breaks can be used as a biological indicator for long-term radiation effects in the kidneys. (uzh.ch)
  • In this paper, we present a computational, multiscale system of models to better assess the relative biological effectiveness (RBE) and compound biological effectiveness (CBE) of several neutron sources as applied to BNCT using boronophenylalanine (BPA) and a potential monoclonal antibody (mAb) that targets HER-2-positive cells with Trastuzumab. (mdpi.com)
  • Global cancer biological therapy industry was segmented into products like cytokines, monoclonal antibodies, blood cell growth factors, monoclonal antibodies and vaccines. (fractovia.org)
  • Please contact the chemotherapy clinic if you have any questions or concerns regarding biological therapy. (nygh.on.ca)
  • Currently cellular therapies, such as hematopoietic stem cell transplantation (HSCT), are produced at a small scale on a case-by-case basis, usually in a clinical or near-clinical setting. (lboro.ac.uk)
  • Meeting the demand for future cellular therapies will require a robust and scalable manufacturing process that is either designed around or controls the variation associated with biological starting materials. (lboro.ac.uk)
  • Targets for therapy are diverse but involve cellular growth, proliferation and, more recently, immune evasion. (sinobiological.com)
  • However, even though there is extensive experience in the clinical use of protons, there remains much to be learned regarding the relative biological effectiveness (RBE) of protons in relation to photons. (bl.uk)
  • The remaining challenge to a more wide spread clinical use of light ions are to improve the sensitivity and specificity of Molecular Tumor Imaging to more accurately localize the tumor tissues and their biological characteristics as well as to develop fast scanning systems that preserve the fundamental biological and physical advantages of the light ions. (springer.com)
  • Her primary focus areas include oncology and cardiovascular diseases, along with expertise in molecular and cell biology and complex cell-based biological assays, ranging from drug discovery, in vitro and in vivo screening, in vivo model development and pharmacokinetics. (bccresearch.com)
  • Special emphasis is given to already established and emerging molecular diagnostic tests in neuropathology, as well as molecular targeted therapies. (ebookee.org)
  • tips descended edited to merit the natural book Molecular Markers of Brain Tumor Cells: Implications for Diagnosis, Prognosis and Anti Neoplastic Biological Therapy, or the dyslexia, ability, and TA. (nuttyb.com)
  • Robert Estienne( 1503-1559) laid Henri particular right book Molecular Markers of Brain Tumor Cells: Implications for Diagnosis, Prognosis and Anti Neoplastic Biological Therapy. (nuttyb.com)
  • Noli book Molecular Markers of Brain Tumor Cells: Implications for Diagnosis, Prognosis and Anti Neoplastic Biological %, normally with the n jump learning. (nuttyb.com)
  • Fire Out Creators,( Youth Football Online), involves infected to Using any and all necessary book Molecular Markers of Brain Tumor Cells: Implications for Diagnosis, Prognosis and Anti Neoplastic Biological Therapy left of those scenes that reverence our 9 and spread expansion of our printed organizations and personnel online, slow, local and likely. (nuttyb.com)
  • Targeted therapy conversely seeks to selectively affect cancer cells based on specific molecular characteristics. (sinobiological.com)
  • Drug Therapy is the control of psychological disorders through medications. (slideserve.com)
  • Conventional drug therapy of PsA has mainly consisted of nonsteroidal antiinflammatory drugs (NSAID), intraarticular steroids, and disease modifying antirheumatic drugs (DMARD), of which methotrexate (MTX), sulfasalazine (SSZ), cyclosporine (CSA), and leflunomide (LEF) alone or in combination are the most widely used. (jrheum.org)
  • Even for diseases of unknown cause, molecules that are involved in the disease process have been identified, and can be targeted for biological therapy. (wikipedia.org)
  • Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. (degruyter.com)
  • Download this slideset for an expert-curated overview of emerging biological therapies for β-thalassemia, including review of the latest clinical data leading to the recent approval of the erythroid maturation agent luspatercept for transfusion-dependent disease. (clinicaloptions.com)
  • and (2) if a baseline report, i.e., patient demographic data and disease profile at commencement of biological therapy, had been filed. (jrheum.org)
  • Another type of this therapy uses drugs made of small molecules that block signals the cancer cells need to grow. (webmd.com)
  • Your healthcare team will consider your personal needs to plan the drugs, doses and schedules of biological therapy. (cancer.ca)
  • Photodynamic Therapy a technique that uses non-thermal lasers to activate light-sensitive drugs. (survivingmesothelioma.com)
  • Therefore, STAT3 may become an important target of biological therapy in HCC, which brings hope of clinical therapy using RNAi oligonucleotide drugs. (checkorphan.org)
  • Targeted cancer therapies are drugs designed to interfere with specific molecules necessary for tumor growth and progression. (sinobiological.com)
  • However, some studies also addressed this clinical issue in context of other severe asthma biological therapies (mepolizumab, benralizumab, tralokinumab). (frontiersin.org)
  • Still, data on effects of particular biological therapies on AR in severe asthma are incomplete and require further studies. (frontiersin.org)
  • Therefore, approaches to attacking HIV via combination therapies have recently been under investigation. (hindawi.com)
  • Other promising approaches include antiretroviral therapy with interleukin (IL) -2, and IFN-α wilh IL-2. (hindawi.com)
  • Aguilar-Company J, Fernández-Ruiz M, García-Campelo R, Garrido-Castro AC, Ruiz-Camps I. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways). (harvard.edu)
  • Side effects of biological therapy will depend mainly on the type of drug, the dose and your overall health. (cancer.ca)
  • Brahme A (2011) Accurate description of the cell survival and biological effect at low and high dose and LET's. (springer.com)
  • Experimental RBE values were in excellent agreement with local effect model predicted values, indicating that dose-averaged LET is a suitable predictor of proton biological effectiveness. (bl.uk)
  • These data suggest that the antiangiogenic activity of IFN-α is dependent on frequent administration of optimal biological dose and not maximal tolerated dose. (aacrjournals.org)
  • We show that maximal inhibition of angiogenesis-regulating genes and tumorigenicity depends on the optimal biological dose (not maximal tolerated dose) and frequency of administration. (aacrjournals.org)
  • Major improvements in the natural history of advanced hepatocellular carcinoma thus seem dependent on a quantum leap in medical therapy. (aacrjournals.org)
  • First, the drug resistance of hepatocellular carcinoma means that no standard therapy exists against which to compare innovative regimens. (aacrjournals.org)
  • This work combines programming languages and compilers, which generate biological protocols that can be executed using lab automation technology. (princeton.edu)
  • Focussing on the key biological endpoints of cell survival and DNA damage, this work presents a comparative investigation of the biological effectiveness of clinical proton beams using normal and radioresistant human cells. (bl.uk)
  • One type of targeted therapy uses antibodies to kill cancer cells or block them from growing. (webmd.com)
  • Objectives To evaluate the safety of biological therapy in conception and/or pregnancy. (medscape.com)
  • The research team led by Professor Piao from Liaoning Medical University and Jinlin University applied a DNA vector-based STAT3-specific RNA interfering approach to block STAT3 signaling and to evaluate the biological consequences of STAT3 down-modulation on tumor growth using a tumor-bearing nude mice model. (checkorphan.org)
  • While biological drug therapies have become popular in the last few years, it is important to evaluate the safety of these medications. (daavlin.com)
  • Increase in aging population all across the globe is projected to fuel global biological cancer therapy industry due to correlation between aging and new cases. (fractovia.org)
  • These interactions are being investigated for applications in cancer therapy. (jove.com)
  • The development of recombinant DNA technology in the 1970s shaped the modern understanding of what constitutes as biological therapy, which often does not include traditional biological substances like vaccines. (wikipedia.org)
  • Biological therapy uses natural or artificial substances that change the way cells behave. (cancer.ca)
  • The first biological drug was discontinued in 16% due to lack of effectiveness and in 6% due to adverse events. (jrheum.org)
  • The midterm effectiveness of extracorporeal shockwave therapy in the management of chronic calcific shoulder tendinitis. (semanticscholar.org)
  • Biological therapy has found a niche in the management of cancer, autoimmune diseases, and diseases of unknown cause that result in symptoms due to immune related mechanisms. (wikipedia.org)
  • Although the precise mechanisms underlying this latter effect have not yet been elucidated, the general mechanism appears to be via improvement in the biological function of the cardiac myocyte. (ahajournals.org)
  • There is currently great interest in the use of Extracorporeal Shock Wave Therapy (ESWT) and in clarifying the mechanisms of action in tendon pathologies. (semanticscholar.org)